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Description 
         Cannabis is a genus of flowering plant that includes one or more species. The plant is believed 
to be indigenous to Central Asia, China, and the north-west Himalayas. The common name for 
Cannabis is hemp, although this term is sometimes used to refer only to strains cultivated for 
"industrial" (non-drug) use. Cannabis plants produce a unique family of compounds called 
cannabinoids, several of which produce psychical and/or physiological effects when 
consumed. The crude drug usually comes in the form of dried flowers and leaves, resin 
(hashish), or various extracts. The cultivation or possession of Cannabis for drug purposes is 
outlawed in most countries. 
 
 
 
 
 
Figure 1 
         Cannabis is an annual, dioecious, flowering herb. The leaves are palmately compound, with 
serrate leaflets. The first pair of leaves usually have a single leaflet, the number gradually 
increasing up to a maximum of about thirteen (usually seven or nine), depending on variety 
and growing conditions. At the top of a flowering plant, this number again diminishes to a 
single. The lower leaf pairs usually occur in their opposite leaf arrangement 
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Taxonomy 
         The genus Cannabis was formerly placed in the Nettle (Urticaceae) or Mulberry (Moraceae) 
family, but is now considered along with hops (Humulus sp.) to belong to the Hemp 
family(Cannabaceae).Various types of Cannabis have been described, and classified as 
species, subspecies, or varieties:  
• plants cultivated for fiber and seed production, described as low-intoxicant, non-drug, or                 
fiber types  
• plants cultivated for drug production, described as high-intoxicant or drug types  
• escaped or wild forms of either of the above types.  
         Cannabis plants produce a unique family of terpeno-phenolic compounds called cannabinoids, 
which produce the "high" one experiences from smoking marijuana. The two cannabinoids 
usually produced in greatest abundance are cannabidiol (CBD) and/or Δ9-
tetrahydrocannabinol (THC), but only THC is psychoactive. 
 
            
 
 
 
 
Figure 3 
  
          Since the early 1970's, Cannabis plants have been categorized by their chemical phenotype or 
"chemotype," based on the overall amount of THC produced, and on the ratio of THC to 
CBD. Although overall cannabinoid production is influenced by environmental factors, the 
THC/CBD ratio is genetically determined and remains fixed throughout the life of a plant. 
Non-drug plants produce relatively low levels of THC and high levels of CBD, while drug 
plants produce high levels of THC and low levels of CBD. When plants of these two 
chemotypes cross-pollinate, the plants in the first filial (F1) generation have an intermediate 
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chemotype and produce similar amounts of CBD and THC. Female plants of this chemotype 
may produce enough THC to be utilized for drug production. 
 
 
 
 
 
 
 
 
 
 
 
 
                                Top of Cannabis plant in vegetative growth stage. 
                                                        Figure 4 
Popular usage 
 
         The National Institute of Drug Abuse defines drug abuse as "the non-medical use of a 
substance for psychic effect, dependence, or suicide attempt.  
         Marijuana (also known as ganja) and hashish are psychoactive products of the plant Cannabis 
sativa L. subsp. indica (= C. indica Lam.). The herbal form of the drug consists of dried 
mature inflorescences and subtending leaves of pistillate ("female") plants. The resinous form 
consists primarily of glandular trichomes collected from the same plant material. It has been 
reported that commercial hashish is often less potent than high quality seedless marijuana.1 
However, carefully produced and screened hashish is at least three times as potent as the 
highest quality herb.2 The major biologically active chemical compound in Cannabis is THC. 
It has psychoactive and physiological effects when assumed, usually by smoking or ingestion. 
The minimum amount of THC required to have a perceptible psychoactive effect is about 5 
mg. A related compound, Δ9-tetrahydrocannabidivarin, also know as THCV, is produced in 
appreciable amounts by certain drug strains. This cannabinoid has been described in the 
popular literature as having shorter-acting, flashier effects than THC, but recent studies 
suggest that it may inhibit the effects of THC. Relatively high levels of THCV are common in 
African dagga (marijuana), and in hashish from the northwest Himalaya 
         The nature and intensity of the immediate effects of cannabis consumption is related to the 
dose, the species or hybridization of the source plant, the modality of consumption, the user's 
psychical and physical characteristics (such as tolerance), and the environment of 
consumption. This is sometimes referred to as set and setting. Smoking the same cannabis 
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either in a different frame of mind (set) or in a different location (setting) can alter the effects 
or perception. What the user does under the influence can also affect the effects of cannabis. 
For example, if the user does nothing they will feel relaxed and sleepy, whereas if they engage 
in intense physical or psychical activity they will feel energised. Effects of cannabis 
consumption may be loosely classified as cognitive and physical. Anecdotal evidence suggests 
that drug varieties of Cannabis sativa subsp. sativa tend to produce more of the cognitive or 
perceptual effects, while C. sativa subsp. indica tends to produce more of the physical effects. 
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                                  ECS (endocannabinoid system) 
 
         The endocannabinoid system includes cannabinoid receptors, their endogenous ligands, the 
anandamide transporter protein and two enzimes, fatty acid amide hydrolase (FAAH) and 
monoglyceride lipase (MGL).3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 
 
                                                         Cannabinoid  receptors 
         Cannabinoid receptor types are denoted by the abbreviation CB and numbered in the order of 
their discovery by a subscript. At present, two cannabinoid receptor types have been 
unequivocally identified, named CB1 and CB2. The CB1 receptor is the most abundant G 
protein-coupled receptor expressed in the brain. Especially in the hypothalamus, pituitary 
gland and in the mesolimbic dopamine circuits. It has detected not only in neurones but also in 
astrocytes and microglial cells. It is also found in a variety of peripheral tissues such as 
adipose tissue, liver, muscle, the gastrointestinal tract, pancreas, urinary bladder, lung, adrenal 
gland, testis, ovary, uterus and prostate and in rat adipose tissue. The CB2 receptor is limited 
essentially to the cells associated with the immune system, like spleen, thymus, and tonsils.4 
CB2 receptors were found to be expressed in brain microglial cells under inflammatory 
conditions,5 and recent studies using human neutrophils indicate that the CB2 receptor may 
suppress neutrophil migration during inflammation.  It is also located in retina6, skin7 and 
some malignant cells.8 
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                                                                           Figure 6 
         The human CB1 and CB2 receptors exhibit 68% identity  within the transmembrane regions, 
44% identity throughout the whole protein. A new putative cannabinoid receptor gene has 
been recently identified in the invertebrate Ciona intestinalis that share 28% sequence identity 
with the human CB1 and 24% sequence identity with the human CB2.9  
                              
Figure 7                                                                                      Figure 8 
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                                  Endogenous ligands of cannabinoid receptors 
         The individuation of endogenous ligands for these receptors has been yielded after 
cannabinoid receptors discovery. The endogenous ligand of the CB1 receptor  is anandamide 
whereas the endogenous ligand of the CB2 is 2-arachidonilglicerolo (2-AG) (Figure 9). They 
are synthesized from membrane-derived phospholipids whose biologic effects are mediated 
through coupling with the specific, widely expressed ECS receptors located presynaptically.10 
The synthesis of anandamide is Ca++-dependent and is produced locally by the phospholipase 
D-mediated cleavage of the membrane precursor called N-arachidonoyl-
phosphatidylethanolamine. While the synthesis of 2-arachidonilglicerolo is produced by the 
DAG lipase cleavage of the membrane precursor. Because endocannabinoids are lipophilic 
compounds derived from membrane phospholipids, they do not need to be stored in synaptic 
vesicles like other neurotransmitters.11 In the brain, they are produced by neurons at their sites 
of action and act on demand, generating a transient, rapid effect before being hydrolyzed and 
inactivated by FAAH.11, 10 Because of their lipophilic nature and the mechanism of their 
synthesis and release, endocannabinoids are considered as local neuromodulators.12 
 
 
 
                                                                               Figure 9 
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                         Signal transduction  activated by cannabinoid receptors 
 
         The protein G, which is coupled to receptor, is constituted by the α and βγ subunits and the G 
protein (Gi/Go) associated to cannabinoid receptors is sensible to pertussis toxin. The affinity 
of CB1 and CB2 for Gi or Go proteins may be different as revealed by several studies on 
cannabinoid ligand binding or regulation of [35 s] GTPγS binding. Whereas, activation of both 
of them display a high affinity for Gi, agonist stimulation of CB1 also result in a high-affinity 
saturable interaction with G0 but CB2 receptor do not interact efficiently with G0. It has been 
reported that the affinity of CB1 receptor for G0 is ten fold higher than that of the CB2.13 It has 
been described that the juxtamembrane C-terminal region of CB1 receptors (amino acids 401-
417) and the second and third intracellular loops are critical for Gi/o protein coupling and that 
the distal C-terminal tail domain profoundly modulates both the magnitude and kinetics of 
signal transduction.14 In the CB2 receptor it has been described the existence of two cysteins, 
C313 and C320, that are located  in this C-terminal region, that may play important roles for 
receptor- G protein coupling and receptor desensitization. Also, the third transmembrane 
domain in the CB2, particularly the Asp-Arg-Tyr motif, may be crucial for interacting with G 
proteins because mutations of highly conserved aspartate residues in the second tranmembrane 
domain receptors have also been described to disrupts G-protein coupling. Some effects are 
independent by interaction with G proteins. The former are negative regulation of adenylate 
cyclase. An effect mediated by G protein is inhibition of calcium channels. In fact 
cannabinoid agonists reduce the amplitude of voltage-gated calcium currents in neuronal cells 
through Gi/o proteins. Cannabinoids also modulate K+ channels and cannabinoid as THC cause 
a depression of inward sodium current determining a depression of action potentials.15,16 CB2 
receptor seem to be independent of channel activation.  
    GPCRs (G protein-coupled receptors) can stimulate the protein kinase (MAPK) cascade and 
induce cellular proliferation. The mammalian MAPK family consists of three subfamilies with 
multiple members: the extracellular signal-regulated kinases (ERK), the Jun amino-terminal 
kinases/stress-activated kinases (JNK/SAPK), and the p38 MAPKs. While ERK is involved in 
regulation of cell division and growth, the other two subfamilies are activated by stress signals 
and inflammatory cytokines and have been related with cellular death and immune disorders.  
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        Figure 10 
 
              
 
          Figure 11 
 
 
                          Biological  roles of endocannabinoids system 
 
         The endo-cannabinoid system is implicated in two major biological roles: modulation of 
neurotransmitter release and modulation of immune functions. Cannabinoids has been 
demonstrated to inhibit the evoked release of Ach, GABA, NA, DA, 5-HT, Glu, Gly, d-Asp, 
and CCK.17 The effect of cannabinoid  on the function of immune cell is still unclear and 
requires elucidation but they produce a deleterious effect on the immune response causing the 
impairment of macrophage functions, perturbation of immunoglobulin production and down-
regulation of immune cells activity. It has been evidenced that THC can suppress the human 
immune response in a host of leukocyte subsets and alveolar macrophages. The degranulation 
of mast cells induced by substance P is fully abrogated by the endogenous ligands at 
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cannabinoid receptors. The mechanism by which CB2 ligands modulate mast cell activation is 
by generating NO and PGE2. It is involved in the controlling vascular homeostasis18 and 
synaptic transmission.19 NO can be induced by proinflammatory factors under pathological 
conditions. NO production is stimulated by anandamide in human monocytes. This 
stimulation could explain some cannabinoids effects like vasodilatation and neurotransmission 
release inhibition. Cannabinoids could be used as therapeutic agents in NO-mediated 
inflammation leading to neurodegeneration. In addition AEA and exogenous cannabinoids 
induce arachidonic acid mobilization and activation of the enzymes of arachidonic acid 
cascade in many cells. It is important to note that AEA degradation into cells by fatty acid 
amide hydrolase (FAAH) yield arachidonic acid that could mediate some biological actions of 
endocannabinoids like vasorelaxation but, in this case, the effect is independent of 
cannabinoid receptors.20 (Figure 12) 
 
 
 
 
                                                                                                                               
                                                                             Figure 12 
         Three enzymes are involved in the release of arachidonic acid from membrane phospholipid 
domain: phospholipase D, phospholipase C and phospholipase A2. The three enzymes have 
been shown to be activated by cannabinoids. PLD cause phospholipid hydrolysis yielding  
arachidonate containing diacylglicerols generation that, after hydrolysis by DAG lipases, may 
release arachidonico acid. The primary pathway is represented by activation of PLA2 which 
liberate arachidonic acid from phospholipids. The main mechanism of cytosolic PLA2 
activation is phosphorylation by MAP kinase. The release of arachidonic acid induced by 
THC in hippocampal neurones can be blocked by the CB1 receptor antagonist SR141716 but 
not by pre-treatment with pertussis toxin, suggesting an involvement of cannabinoid receptor 
by a mechanism independent of Gi coupling. It has been recently shown that cannabinoids 
may modulate arachidonate metabolic enzymes. In human platelets THC inhibit COX-2 
activity blocking the synthesis of its pro-inflamatory metabolites with the redistribution of 
 12
products towards lipoxygenase pathway.21 In human neuroglioma cells THC and 
methanandamide stimulated COX-2 mRNA expression and subsequent PGE2 synthesis via a 
non cannabinoid receptor-mediated mechanism. 
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Role of cannabinoids 
 
         For over 4000 years, Cannabis sativa L extract have been widley used as recreazional drug 
and as therapy for a variety of disorders. The discovery of psychoactive principle of Cannabis 
sativa, delta 9-tetrahydrocannabinol initiated research into the physiological role of 
cannabinoids. In the last years our understanding has been modified significantly by new 
discovery. 
        Cannabinoids are best know for their effects on CNS functions. They produce euphoria, 
alterations in cognition and analgesia, have anticonvulsivant properties and affect temperature 
regulation, sleep and appetite. However, cannabinoids also possess immunomodulatory 
activity and anti-infiammatory properties. Many disease of the CNS including Alzeimer 
disease, Parkinson’s disease,  AIDS dementia and mainly multiple sclerosis (MS) involve 
inflammation, and cause an upregulation of cytochines and other infiammatory mediators in 
the CNS; Therefore cannabinoids may be potential therapeutic agents in neurological diseases. 
         Recent studies revealed mainly role of cannabinoids in: 
         Cognition: the most prominent among the various consequences of CB1 receptor activation by 
exogenous agonist are disrupotive effects on woking meoty, i.e. on processes necessary to 
learn and react to new information that differs from session to session. 
         Emotionally: blockade of CB1 receptors by SR141716A caused an increase in anxiety-related 
behaviour. 22, 23, 24 In contrast , lower doses of  SR141716A had no effects.25 Data obtained in 
mice were more inconsistent. Administation of SR141716A either decreased26 or increased 
anxiety-related behaviour, depending on the genetic background of animals and the test 
situation. 
        Multiple sclerosis (MS): is the most important chronic inflammatory demyelinanting disorder 
of the CNS. The cannabis and cannabinoid agonist may be effective in ameliorating 
symptomatology of MS, especially spasticity and pain. The benefical effects of cannabinoids 
agonist the symptomatology associated with chronic inflammatory demyelinnanting 
pathologies, may be exerd at multiple levels: by improving motor function, by limiting 
neuroinflammation, by promoting remyelination. 
         Immune modulation: the cannabinoid CB2 receptor is expressed abundately in various types of 
inflammatory cells in particolary in B cells. The CB2 receptors has been associated with most 
of immunomodulatory activity of cannabinoids, but also CB1 may be linked to cannabinoid-
mediated alterations of immune cell reactivity. Cannabinoids exibit immunosopressive 
properties.  
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         Appetite and energy regulation: the ECS is postulated to connect the physical and emotional 
responses to stress with appetite and energy regulation (general stress-recovery system). 
Stimulation of the ECS may possibly occur as a consequence of obesity, leading to increased 
levels of endocannabinoids, which disrupt the feedback mechanism involved in energy 
balance. The ECS affects energy balance, glucose homeostasis, and lipogenesis because of  
the cannabinoids receptors are located in the adipose tissue, the liver, the pancreas and the 
skeletal muscle (Figure 13).  
         Obesity: activation of the ECS increases food intake and promotes weight gain. The blockade 
of the CB1 receptor reduces body weight in animals through central and peripheral action. 
 
 
                    
Figure 13 
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Other Functions of the ECS 
         The ECS appears to play an important role in the regulation of hormonal balance through 
actions on endocrine axes. In general, the ECS has been shown to inhibit hypothalamic-
pituitary-adrenal functions and to modulate fertility. Recent data demonstrate that FAAH 
protein expression and activity varies as a function of the mouse estrus cycle27 and that CB1 
receptor expression and function correlate with larval organogenesis of Xenopus laevis.28 In 
rats, the CB1 receptor has been shown to mediate cardiopressor and vasodilator effects of 
endogenous AEA29 and in mice AEA was shown to modulate cough sensitivity.30 Other 
functions of the ECS in normal physiology may be related to immune modulation, 
neuroprotection, and bone mass regulation.31-37 Taken together, these data indicate the ECS 
has pleiotropic functions with important implications for human physiology. 
                                                  Pharmacological role of CB2 receptors  
         The physiological and putative therapeutic potential of the CB2 receptor largely remains 
unexplored; however, recent data indicate that CB2 cannabinoid receptors participate in the 
control of peripheral pain, inflammation, osteoporosis, growth of malignant gliomas, tumors 
of immune origin, and  immunogical disordes such as multiple sclerosis. Recent studies have 
now implicated CB2 receptors in neuroprotective activity of cannabinoids, mainly through a 
series of glia-dependent anti-inflammatory actions.7 
     
Amyotrophic lateral sclerosis 
 
Amyotrophic lateral sclerosis (asl), is a neurodegenerative disease characterized by rapid 
progressive degeneration of motor neurons in the brain and spinal cord, paralysis and death 
within 2-5 years   from the diagnosis.38 Asl is the third most common neurodegenerative cause 
of adult death, after Alzheimer’ s disease and Parkinson’s disease.39 Most cases of asl are 
sporadic and are probably acquired, while approximately 10% are familial. Despite a  variety 
of putative underlying oxidative stress, neuroinflammation, autoimmunity, a defect in 
neuronal glutamate transport, glutamate toxicity and mutations of superoxide dismutase 
gene.40 Recent evidence indicates that asl is a disease characterized by chronic 
inflammation.41, 42  Microglia are the resident macrophages of CNS and in response to CNS 
injury microglia quickly convert to on “active” state during which they change to on 
amoeboid shape, up-regulate the cell-surface expression of a variety of surface antigens and 
 16
secrete several pro-inflammatory molecules43 including interleukin-1β, tumour necrosis 
factor-α, nitric oxide,43 oxygen radical, glutamate, proteases and contribute to the 
pathogenesis of neurologic disorders.  The microglial activation in the CNS suggest a primary 
neuroinflammatory state with deleterious effects on surrounding neurons.44 Recent study 
reported elevated levels of CB2 receptors in microglia isolated from post-mortem human 
spinal cord of ASL patients45 moreover recently in vitro studies demonstrate that CB2 
receptors are up-regulated in microglia in response to inflammatory stimuli46 and that CB2 
agonist suppress microglial activation.47 In 2005 Jared Ehrart et al showed that the CB2 
agonist JWH 015 inhibits INF-γ- induced microglial CD40 expression. They proved that when 
CB2 is stimulated by the presence of  JWH 015 the pro-inflammatory molecules were 
significantly reduced. Recent Studies demonstrate that treatment at onset with the non 
selective CB1/CB2 agonist Win 55-212 produces a significant rightward shift in the survival 
curve on G93A mice reflected by an increase of 8.8 days in the survival interval. 
Administration of the selective CB2 agonist AM1241 results in a highly significant extension 
of survival with mice living 56% longer after symptom onset than controls. These results 
suggest that CB2 agonist may be effective as pharmacological agents with several distinct  
advantages for the management of this devastating disease.48 
 
Pancreatic cancer 
 
Pancreatic cancer is one of the most malignant and aggressive forms of cancer.49 About 95% 
of pancreatic cancers cases are ductal adenocarcinomas. The anatomic localization of the 
pancreas and the non-specific nature of the symptoms result in a complex and delayed 
diagnosis. The 85% of patients show metastasic infiltrations in proximal lymphatic nodes, 
liver, or lungs, and only 15% to 20%49 of the tumors are typically found rescetable. <20% of 
the operated patients survive up to 5 years. However the median survival for the affected 
patients remains about 1 years. The department of biochemistry and molecular biology I of 
university of Madrid and institute national de la Sante et de la Recherche Medical of France 
investigated the effect of cannabinoids on pancreatic tumor cells. First, they determined the 
expression of cannabinoid receptors in four different human pancreatic tumor cell lines: Panc 
1, MiaPaCa 2, Capan 2 and BxPc 3 cell lines. In these cells, mRNA for cannabinoid receptors, 
was expressed whereas mRNA levels for these receptors were very low in normal pancreatic 
tissue.50 This difference was confirmed by immunofluorescence analysis of CB receptors both 
in human biopsies from pancreatic cancer and in pancreatic tumors generated in mice. Next, 
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they incubated these cells with THC and observed a decrease in cell viability in the four lines 
tested. The MiaPaCa 2 cells were the most sensitive,  whereas Panc1 were the less. Incubation 
with the CB2 selective antagonist SR144528 but not with the CB1 selective antagonist 
SR141716, prevented THC-induced loss of cell viability in both lines. THC led to caspase 3 
activation, a characteristic of apoptotic cell death.50 The stress-regulated protein p8 is involved 
in THC-induced apoptosis of pancreatic tumor cells. Next, they identified genes downstream 
of p8 that could participate in the antitumoral effect of THC. To evaluate the antiproliferative 
effect of cannabinoids on pancreatic tumors in vivo, they first generated tumor by s.c. 
injection of MiaPaCa2 cells in immunodeficient mice. The treatment with THC or the CB2 
selective cannabinoid agonist reduced the growth of the pancreatic tumors. The synthetic 
cannabinoid agonist (WIN 55,212-2) induces apoptosis of pancreatic cancer cells via the same 
endoplasmatic reticulum stress-related proapoptotic pathway as THC. The cannabinoid 
treatment decreases the growth and spreading of pancreatic tumor cells not only to adjacent 
locations but also to distal tissues.50 
 
Inflammation 
        Activation of cannabinoid CB1 and CB2 receptor subtypes suppresses pain behaviour resulting 
from tissue injury and inflammation. The ability of peripheral cannabinoid mechanisms to 
modulate the development of inflammatory nociception is well established, less is known 
about peripheral cannabinoid antihyperalgesic mechanisms after the establishment of chronic 
inflammation. Local administration of agonist suppressed tactile allodynia and mechanical 
hyperalgesia with the expected pharmacological specificity. However, antihyperalgesia 
efficacy and pharmacological specificity for the CB2 selective agonist was less robust in 
testsof thermal compared to mechanical hypersensitivity. Local administration of 
cannabinoids suppress capsaicin-evoked calcitonin gene-related peptide release in rat spinal 
cord in vitro,51 suggesting a possible neuronal mechanism of action.CB2 receptor protein has 
been identified in microglial cultures of neonatal rat spinal cord,51 suggesting the existence of 
additional non-neuronal substrates capable of mediating the antihyperalgesic actions. 
Activation of CB2 receptor on skin keratinocytes stimulates production of β-endorphin to 
induce antinociception through activation of μ-opioid receptor.52 Locally administered CB1 
and CB2 selective agonists (respectively ACEA and AM 1241)induced qualitatively similar 
suppressions  of allodyna and hyperalgesia. Local administration of either ACEA and AM 
1241 at site of inflammation may suppress antihyperalgesic efficacy by reducing primary 
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afferent sensitization, effects consistent with the observation that cannabinoids suppress 
capsaicin-evoked calcitonin gene-relatedpeptide release.51,53  Carrageenan  also enhances C-
fibre-mediated responses and windup in spinal dorsal horn neurons effects, that enhance spinal 
neuronal excitability. These effects are also modulated by both CB154 and CB2 specific 
mechanisms.55 
Inhibition of tumor angiogenesis by cannabinoids 
         Active angiogenesis is involved in the progression of the majority of solid tumors. The 
vascular endothelial cells, like glioma cells, express functional CB2 receptors. The treatment 
with CB2 cannabinoid agonist, as JWH-133, inhibits angiogenesis not only by targeting 
vascular endothelial cells directly, but also by interfering with proangiogenic factor 
expression.56 Cannabinoid administration reduced the expression of vascular endothelial 
growth factor (VEGF), the most potent and ubiquitous proangiogenic factor and of 
angiopoietic 2 (Ang2), which also contributes to the angiogenic process. Cannabinoid 
treatment decreased the activity and expression of matrix metalloproteinase-2 (MMP-2), a 
proteolytic enzyme that allows tissue breakdown and remodelling during invasive 
angiogenesis, whereas tissue inhibitor of metalloproteinase 2 (MMP-2) expression remained 
unaffected.56 Therefore cannabinoids prevent blood vessel formation by inhibition vascular 
endothelial cell migration and survival. Cannabinoids induce apoptosis of tumor cells and 
suppress proangiogenic factor and MMP production, further blocking tumor growth and 
angiogenesis.  
Bone mass 
         In vertebrates, bone mass and shape are determined by continuous remodelling consisting of 
the concerted and balanced action of osteoclasts, the bone resorbing cells, and osteoblasts, the 
bone forming cells. Osteoporosis results from the impairment of this balance, leading to bone 
loss and increased fracture risk.57 It has been recently reported that bone remodelling is 
subject to central through patways that involve signalling by the hypothalamic receptors for 
leptin and neuropeptide Y58,59 which are also associated with the regulation of 
endocannabinoid brain levels.60 Osteoblasts, osteoclasts and their precursors express 
cannabinoid receptor (CB2). The endocannabinoid system is essential for the maintenance of 
normal bone mass by osteoblastic and osteoclastic CB2 signaling. A CB2 specific agonist 
regulates the activity of these cells and attenuates ovariectomy (OVX)- induced bone loss. It 
enhances endocortical osteoblast number and activity and restrains trabecular 
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osteoclastogenesis. CB2 is expressed also in macrophages and immune cells. CB2 agonists 
inhibit the expression of proresorptive cytokines, such as TNF and IL-1.61 CB2 activation 
stimulates the expression of IL-1 receptor antagonist, which is normally present in bone and 
suppresses osteoclast formation.57 In addition, endocannabinoids enhance NO synthase 
activity and its release from monocytes and mast cells.62,63 NO inhibits bone formation and 
resorption64 and therefore this endocannabinoid activity is consistent with the CB2 mediated 
suppression of bone remodelling implied by the high bone turnover in the CB2-null mice. 
Prevention of Alzheimer’s disease 
         Alzheimer’s disease, the most common form of  dementia, is characterized by the deposition 
of β-amyloid peptide. This deposition induce microglial activation.65, 66 CB2 receptors are 
localizated in microglial cells. Cannabinoid receptor activation protects hippocampal or 
granule cerebellar neurons from excitotoxicity. In vivo cannabinoids decrease hippocampal 
neuronal loss and infarct volume after cerebral ischemia, acute brain trauma and ouabain- 
induced excitotoxicity.67 These effects have been ascribed to inhibition of glutamate 
transmission, reduction of calcium influx, and subsequent inhibition of noxious cascades, such 
as tumor necrosis factor-α-generation and oxidative stress.  
Cannabinoids induce glioma stem-like cell differentiation and inhibition gliomagenesis 
         Malignant gliomas remain the most deadly human brain tumors. A characteristic of gliomas is 
their molecular and cellular heterogeneity. Recent findings support the existence of a stem 
cell-derived origin for different types of cancers.68,69 In particular, glioma-derived stem-like 
cells (GSCs) have been isolated from both human brain tumors70-74 and several glioma cell 
lines. GSCs are crucial for the malignancy of gliomas76 and may represent the consequence of 
transformation of the normal neural stem cell compartiment.75 The department of 
biochemistry and molecular biology I of university of Madrid, the department of medical 
chemistry and natural products of Hebrew university and the research unit of La Paz 
university hospital Madrid showed that GSCs express different elements of the CB system 
including G protein-coupled receptors (CB1 and CB2), the ionotropic receptor TRPV1 and 
eCB-degrading enzymes. Cannabinoid receptor are expressed and functionally active in neural 
progenitors in which they regulate cell proliferation and differentiation. In fact the 
cannabinoid agonista promote GSC differentiation and reduce gliomagenesis in vivo. The 
malignancy of human brain tumors inversely correlates with their degree of differentiation 
whereas their mitotic activity is inversely correlated with their increased expression of mature 
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glial and neuronal markers. To identify the potential action of cannabinoids on GSCs, they 
investigated the changes in gene expression induced by the synthetic cannabinoid agonist HU-
210 in GBM-GSCs. It significantly altered the expression of 11 genes of the 266 genes 
analyzed.76 Among them , seven genes involved in regulation of the cell cycle and cell 
proliferation (CDK4, CDKN1B, FGFR1, FGFR3, EGF receptor) were downregulated by 
cannabinoid stimulation. The transcript levels of neuronal MAP2 and the tumor suppress 
RBL1 were increased. These results suggest that CB receptor activation regulates essential 
GSC functions such as cell proliferation and differentiation. CB1 receptor activation resulted 
in increased expression of the early neuronal marker β-tubuline III. U87-MG-GSCs previously 
cultured in the presence of HU-210 or JWH-133 were less efficient as tumor-initiating cells, 
moreover cannabinoid-treated GSCs generated tumors with a lower growth rate, resulting in 
smaller tumor size compared with vehicle-treated cells. Tumors generated by cannabinoid-
treated GSCs showed decreased neurosphere-forming activity and reduced cell proliferation. 
These observations confirm that cannabinoids inhibit stem-like cell-initiated gliomagenesis.76  
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Figure 14 
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Figure 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23
                                          Agonist and antagonist CB2 
         In pharmacology  an agonist  is a substance that binds to a specific receptor or specific 
receptor and triggers a response in the cell. It mimic the action of an endogenous ligand  (such 
as hormone or neurotrasmitter) that binds to the same  receptor. Although many cannabinoid 
receptor ligands show little, or at best modst, selectivity for either receptor, a number of 
synthetic compouds are known which have significant selectivity for the CB2 receptor. These 
include cannabinoid indoles, traditional dibenzopyran and tricyclic pyrazoles. 
Agonist: 
          Indoles : Following the observation that WIN-55,212-2 shows significant CB2 selectivity 
(Ki= 3.3 nM CB2, Ki= 62.3 nM CB1), Showalter et al. Investigated the structure-activity 
relationship of ligands for the CB2 receptor and found that JWH-015 has high affinity for the 
CB2 receptor. Almost simultaneously the Merck Frosst group repoted that several indoles 
structurally related to L768242 are selective for CB2 receptor (Ki=14 nM). 
 
 
JWH-01512    Ki CB2  13.8 nM 
                       Ki CB1  383 nM   
 
 
 
                   L76824213  Ki CB2  14 nM 
                               Ki CB1  2043 nM 
 
 
 
         Traditional dibenzopyran: The traditional cannabinoids, such as Δ9-THC have similar 
affinities for both receptors. Several years ago it was found that 1-methoxy-Δ8-THC-
DMH(L759633, JWH-143) and 1-methoxy-Δ9-THC-DMH (L759656, JWH-142) both have 
high affinity for the CB2 receptor. But 1-deoxy-Δ8-THC-DMH (JWH-057) has considerably 
greater affinity for the CB2 receptor. These observations led Huffman et al. to prepare a 
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number of 1-deoxy-Δ8-THC analogues in particular JWH-056, JWH-139, JWH-133, JWH-
065 have high affinity for the CB2 receptor.  
                                                                                                                  
 
 
                                       DMH                                                                 DMH                                                    DMH 
        L759633                                                 L759656                                          JWH-057 
 
                                                                                                                       
 
 
 
           JWH-056                                                   JWH-139                                     JWH-133 
  
 
 
 
         JWH-065 
         Tricyclic pyrazoles: several of which are highly selective for the CB2 receptor [40]. These 
compounds were based on the Sanofi CB1 and CB2 inverse agonists, SR141716A and 
SR144528, but with the addition of a one carbon bridge from C4 of the pyrazole to the ortho-
position of the C5 aromatic ring. Moreover they contain a relatively small substituent at C-6 
O
O
O
O
O
O O O
O
 25
of the aryl group at C-5 of the pyrazole ring.  The highly selective compound yield chloro 
substituent in 5 on aryl group.  
 
 
 
 
 
 
 
 
 
               Inverse agonist : is an agent which binds to the same receptor binding-site as an agonist for      
that receptor but exerts the opposite pharmacological effect.  
          BML-190 is an inverse agonist, this compound has at best modest affinity for the CB2     
receptor ( Ki 435 nM). 
 
 
 
 
 
 
 
Antagonist:  
AM630 has been demonstrated to be a cannabinoid receptor antagonist in the mouse brain and 
vas deferens. Studies conducted in guinea pig brain reveal that AM630 antagonizes the 
stimulatory effect of the cannabinoid agonist WIN 55,212-2 on [35SlGTFjS binding. 
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SR144528 : is a   CB2 receptor-selective cannabinoid antagonist. In the GTPγS binding assay, 
SR144528 antagonized a number of cannabinoid receptor agonists (KB values ranging from 
26.3 to 76.6 nM) in rat cerebellar membranes and in rat whole brain membranes (KB=50.8 
nM). SR144528 also antagonized CP 55,940-stimulated GTPγS binding in a CB2-expressing 
cell line (KB=6.34 nM).      
 
                      
 
SR 141716: is a CB1 cannabinoid antagonist. 
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Introduction of experimental part 
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INTRODUCTION OF EXPERIMENTAL PART  
 
PART 1 
  
Models of the CB1 and CB2 receptors were generated using the bovine rhodopsin structure 
determined at 2,8 Å as a template using an automated docking approach (AUTODOCK 3.0). 
The length of the transmembrane helices of the two receptor was defined by aligning the 
rhodopsin primary sequence with both receptor sequences. Some aminoacids of the rhodopsin 
were replaced with well-known aminoacids of CB receptors to obtain the three dimensional 
model.77 
 The optimization of the model had been obtained  through docking of WIN55212-2, an 
agonist of the cannabinoids receptors which shows a high activity in both receptors in 
particular CB2, and of anandamide (AEA), the most well-known endogenous ligand and 
which has a completely different structure with respect to WIN55212-2.  
 
         
          WIN55212-2 
 
 
 
          
 
         AEA 
Both receptors showed two binding pocket that are delimited by the transmembrane domain 3 
(TM3), TM4, TM5 and TM6. 
WIN55212-2 had been inserted with the morpholinic group positioned between TM3 and 
TM4, while the naphthyl substituent was directed toward the central core of TM5 and TM6. In 
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this manner, the lipophilic core of the ligand was able to interact with W5.43 (TM5) and 
W6.48 (TM6), (figure 16) and in the CB2 receptor the naphthyl ring with F5.46 (TM5) and the 
morpholinic group with S3.31 (TM3) (figure 16). Therefore in the CB1 the binding site is 
characterized by a lipophilic pocket delimited by F3.36 (TM3), W5.43 (TM5) and W6.48 
(TM6), which principally interact through aromatic stacking with the naphthyl and indole ring 
system, while the morpholinic group is positioned in a secondary lipophilic pocket formed by 
L3.26 (TM3), P4.60 (TM4) and L4.61 (TM4). The CB2 binding site is similar to the CB1 one 
but the WIN55212-2 has a slightly different orientation. In the CB2 site the ligand interacts 
with F5.46 (TM5) and not with F3.36 (TM3) to stabilizing the naphthyl ring. Regarding the 
secondary lipophilic pocket in which the morpholinic group is positioned, the substituent 
interacts with L3.27 (TM3), P4.60(TM4), L4.61 (TM4) and S3.31 (TM3) forms a hydrogen 
bond with the oxygen atom of the morpholinic group (figure 16). Both receptors show a large 
lipophilic pocket occupied by the naphthyl and indole ring of WIN55212-2 and a secondary 
one corresponding to the morpholinic position.  
 
 
Figure 16 
 
 In order this investigation continued with the study of  relevant  literature indole ligands that 
problaby interact in the  WIN55212-2  binding site and that were docked into the CB2  model. 
The indole derivatives show a binding position very similar to the one observed for 
WIN55212-2 . 
The indole  JWH-007 and analog compounds as JWH-015 are less potent than WIN55212-2 .      
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JWH-007 
 
              
 
 
JWH-015 
 
This because the indole ring interacts with L3.26 (TM3), I3.29 (TM3) and L6.59 (TM4). The 
pentyl substituent is inserted into the secondary lipophilic pocket formed by L3.27 (TM3), 
P4.60 (TM4) and L4.61 (TM4), but of course it is not able to form the H bond with S3.31 
(TM3) and this could be one of the reasons for the lower affinity of this ligand, compared with 
that of the WIN55212-2 affinity.  
The indole derivatives bearing the morpholinic ring linked to the C3 position of the indole 
system and the aromatic group linked to the N1 position (in an opposite manner compared 
with WIN55212-2)  show a different placement of the indole ring in the CB2 binding site, 
compared with the indole position of the 3-(1-naphtoyl)indole analyzed. (see JWH-007) 
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indole J 
 
In particular for indole J the substituent  position  3 (acetylmorpholine) is inserted into the 
secondary lipophilic pocket and forms the H bond with S3.31, while the benzoyl substituent 
interacts with W5.43, F5.46. Comparing the position JWH-007 with the compound J  we 
observe that the aromatic and morpholinic group have the same disposition, but for this 
reason, unlike JWH-007, the indole ring of compound J is upset, with the nitrogen directed 
toward the intracellular side of the receptor. These observation might suggest that the nitrogen 
of the indole system should not be important for the interaction, and that the role of the whole 
indolic system could be only that of an aromatic core able to place the substituents in the right 
disposition in the CB2 receptor binding site.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
                                     JWH-007                                                                         Indole compound J 
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Superimposition of the two ligands: JWH-007 and compound J. 
 
These analysis suggest that the CB2 binding site is similar to the CB1, with a primary 
lipophilic pocket delimited by F3.36, W5.43, W6.48 (TM5 and TM6) and the secondary 
lipophilic pocket delimited L3.27, P4.60, L4.61 and Ser3.31 (TM3 and TM4). An analysis of 
the interaction of some agonists with both receptors showed that CB2/CB1 selectivity is 
mainly determined by the presence of the nonconserved residue S3.31 (TM3) and F5.46 
(TM5) in CB2. These residues are localized in the binding pocket that is delimited by TM3, 
TM4, TM5 and TM6 (Figure 17). 
 
 
 
 
 
 
                                                                                      
 
 
 
 
 
 
 
 
 
 
 
The binding pocket of the CB1 receptor.                    The binding pocket of the CB2 receptor. 
Figure 17 
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Previously were synthesized a serie of 1,8-naphthyridin-3-carboxamide derivatives of general 
structur A.78 These compounds are characterized by the presence of important structural 
requirement shown by other classes of cannabinoid ligands, such us an aliphatic or aromatic 
carboxamide group in position 3, present in quinoline derivatives like JTE-907 and in 
arylpyrazole derivatives like SR-144528, and alkyl or arylalkyl substitutent in position 1, 
present in aminoalkylindole derivatives like WIN-55212-2 and SR-144528.  
 
 
 
 
 
                                                                          A       
                              
                        SR-144528                                                                 JTE-907                                  
                                                   
 
 
 
 
The binding results of these compounds for CB1 and CB2 receptors were  assessed by 
competition experiments with [3H]CP-55,940 in mouse cerebral membranes and mouse spleen 
homogenate, respectively.78 
The results obtained show that the 1,8-naphthrydine derivatives examined generally exhibit a 
higher affinity for the CB2 receptor than for the CB1 receptor. Furthermore, some of these 
compounds showed a good CB2 selectivity with the CB1/CB2 ratio  >20. It was also possible 
to hypothesise that in order to obtain a good affinity on the CB2 receptor, the presence is 
necessary in position 1 of a n-alkylic or benzylic substituent, which my be substituted, and in 
position 3, of a aliphatic carboxamide, such us cyclohexylamide directly linked to the 1,8-
naphthyridine nucleus. 
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Bearing this in mind, I designed and synthesized new 7-methyl-1,8-naphthyridin-4(1H)-on-3-
carboxamide derivatives (structure A n=0), analogues derivatives  in which the methyl group 
was removed or substituted with a chlorine atom, fluorine atom, metoxy group and 
dimethylamino group and new quinolin-4(1H)-on-3-carboxamide derivatives of general 
structure B.  
 
 
                                                                                                                                                                                    
           
           
 
 
 
  The synthesis of the new  1,8-naphthyridine derivatives are  described in Schemes 1-5. As 
reported in Scheme 1 the treatment of 2-amino-6-methylpyridine with 
ethoxymethylenemalonic acid  diethyl ester (EMME) at 110°C for 2h gave the diethyl ester 
derivative 1, which was heated in dowtherm A for 1h to give the derivative 7-methyl-1,8-
naphthyridin-4(1H)-on-3-carboxylic acid ethyl ester 2.79 The heating of ester 2 with the 
suitable amine provided the corresponding amide derivatives 3-5.
The treatment of carboxamide derivatives 3-5 in anhydrous DMF with NaH for 1 h and then 
with the appropriate benzyl chloride or arylalkyl chloride or 4-(2-chloroethyl)-morpholine 
provided the desired 1,8-naphthyridin-4-one derivatives 6-14 (Scheme 1).80 
The treatment of 2,6-diaminopyridine with acetyl chloride in anhydrous dioxane at room 
temperature for 2 h gave acetyl derivative 15, which was purified by flash-chromatography 
(AcOEt). The 7-acetamido-1,8-naphthyridin-4(1H)-on-3-carboxylic acid ethyl ester 16 was 
synthesized following the method reported in literature. 81 
Compound 16 was heated at 120 °C in sealed tube with  4-methylcyclohexylamine or 
cyclohexylamine for 24h (Scheme 2). Under these conditions, the hydrolysis of the acetamido 
group also takes place, and thus, the 7-amino-3-carboxamide derivatives 17 and 18 
respectively were obtained. Diazotization of these compounds carried out in aqueous 37% 
hydrochloride acid at 40°C for 3h afforded the 7-chloro derivatives 19 and 20, (Scheme 3) 
which, by reaction with benzyl chloride or arylalkyl chloride or 4-(2-chloroethyl)-morpholine, 
in the same condition above reported gave the desired compounds 21-25 (Scheme 3). The 
diazotization of  compound 18,83 carried out in aqueous 50% thetrafluoroboric acid at –5°C 
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during the addition of the NaNO2 and then at r.t. for 1h 30 min, gave the corresponding 7-
fluoro derivative which was purified by flash-chromatography. The treatment of carboxamide 
derivative 26, in anhydrous DMF with NaH for 1h and then with the 4-(2-chloroethyl)-
morpholine for 24h provided the desired derivative 27. The reaction of the compound 22 with 
the sodium metilate, prepared from sodium in MeOH,  at 80°C for 5h 30 min, gave the 
derivative 28 (Scheme 3). 
The 7-chloro derivative 20, by reaction with dimethylamine in sealed tube a 120°C for 24h 
gave the N,N-dimethylamino derivative 29 (Scheme 4). The treatment of carboxamide 
derivative 29, with NaH and then with the 4-(2-chloroethyl)-morpholine provided the desired 
compound 30. The carboxamide 31 was obtained by dehalogenation of  20 with H2 in the 
presence of Pd/C as a catalyst. The treatment of carboxamide derivative 31, in anhydrous DMF 
with NaH for 1h and then with  benzyl chloride or arylalkyl chloride or 4-(2-chloroethyl)-
morpholine, gave the desired compounds 32-34 (Scheme 4). 
As reported in Scheme 5, the diazotization of compound 1878 with NaNO2 in aqueous 96% 
sulfuric acid gave the 7-hydroxy derivative 35, which, by reaction with o-fluorobenzyl 
chloride under the same conditions described above, gave N-cyclohexyl-1-(o-fluorbenzyl)-7-
(o-fluorobenzyloxy)-1,8-naphthyridin-4(1H)-on-3-carboxamide 36. 
 The synthesis of the new  quinoline-4(1H)-on-3-carboxamide derivatives are  described in 
Scheme 6. 
The suitable aniline was heated with EMME to gave the diethyl ester derivatives 3783-39. 
Successful these compounds was heated in dowtherm A for 1 h to afforded the 7-substituited 
ethyl ester 40-42.  
The heating of  ethyl ester 40-42 with the appropriate amine at 120°C for 24h in sealed tube 
provided the carboxamide derivatives 43-46 (Scheme 6). The treatment of carboxamide 
derivatives 43-46 in anhydrous DMF with NaH for 1 h and then with the suitable benzyl 
chloride or 4-(2-chloroethyl)-morpholine provided the desired compounds 47-54 (Scheme 6).
 36
The studies of automated docking have showed that all the 1,8-naphthyridine derivatives 
tested could form an intramolecular H bond between the carbonylic oxygen and the amidic 
NH, creating a pseudocycle planar with the naphthyridine ring (structure C), and our studies 
suggested that this interaction was quite strong.77  
 
 
 
 
 
 
 
 
 
To verify the ability of our CB2 model to discriminate between active and inactive ligands and 
also to verify whether the formation of a planar pseudocycle was important for interaction 
inside the CB receptor, I synthesized to tested some new compounds characterized by: 
• the presence of a hydroxy group in position 4 of the naphthyridine nucleus, instead of 
the carbonyl oxygen atom, and by partial removal of the aromaticity of the cycle.( 
general structure D). 
• closing of the O in position 4 with the amidic NH in a cycle to five atoms, to mime 
the pseudocycle planar of the energetic form more stable. (general structure E). 
• shifting from position 3 to  position  2 of the heterocyclic nucleus, of the carboxamide 
group ( structure F). 
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The synthesis of  compounds of general structur D is outlined in Scheme 7. The reaction of 
the 1,8-naphthyridin-4-one derivatives78 55-57 with sodium borohydride in anhydrous ethanol 
gave the N1-substituted 4-hydroxy-7-methyl-1,2,3,4-tetrahydro-1,8-naphthyridin-3-
carboxamides 58-60. 
The synthesis of 3H-pyrazol-[4,3-c]-quinolines 66-70 is reported in Scheme 8. When the 
quinolin-4(1H)-on-3-carboxylic acid ethyl esters 39 and 4083 were heated with phosphoryl 
trichloride at 120°C for 15 min the corresponding ethyl 4-chloro-3-quinolinecarboxylate 61 
and 6285 were formed. These intermediates were subsequently converted into compounds 63-
65 by reaction with the appropriate hydrazines in xylene at 150 °C for 13 h (73–80% yields). 
The reaction of these with benzylchloride or 4-(2-chloroethyl)-morpholine hydrochloride 
under the same conditions described above gave the desired compounds 66-70 (30–60% 
yields). 
The synthesis of compounds of structure F is  outlined in Scheme 9. 
The derivative 7-acetamido-1,8-naphthyridin-4(1H)-on-2-carboxylic acid methyl ester 7285 
was synthesized following the method reported in the literature starting from 2-acetylamino-6-
aminopyridine 15 with acethylendicarboxylic acid dimethyl ester at 180°C for 24h, and than 
was heated in Dowtherm A for 1h and was purified by flash-chromatography (AcOEt/MeOH 
10:1).   
The heating of 72 at 120 °C in  sealed tube with cyclohexylamine for 24 h affording the 7-
amino-2-carboxamide derivative 73. This compound, by reaction with benzylchloride under 
the same conditions described above, gave the 1,8-naphthyridine derivative 74  in very low 
yield. 
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Results and discussion 
 
CB1 and CB2 affinity 
 
Affinities at CB1 and CB2 receptors for the 1,8-naphthyridin-4(1H)-on-3-carboxamide 
derivatives 6-14, 21-25, 32-36, 58-60,  were determined by measuring their ability to displace 
[3H]CP-55,940 from its binding site in a membrane preparation from mouse brain (minus 
cerebellum) and mouse spleen homogenate, respectively. 
For  the compounds 7 and 8 and for the other compounds 27-30, 47-54, 66-70 and 74  the 
binding assay  were tested using membranes from HEK-293 cells transfected with either the 
human CB1 and CB2 receptors. 
The CB1 and CB2 receptor binding assay results for the new compounds are summarized in 
Table 1. The Ki values of WIN-55,212-2, HU-210, AM630, JWH-133, ACEA, SR141716A 
and SR144528 are also included in the table as reference compounds for the CB1 and CB2 
cannabinoid receptors. 
The results obtained for the compounds 7 and 8, show that there are not  substantially 
differents between the Ki values obtained utilizing  membrane preparation from mouse brain 
(minus cerebellum) and mouse spleen homogenate, and membranes prepared from HEK-293 
cells. For this reason the SAR was made considering the totality of 1,8-naphthyridin-4-one 
derivatives. 
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Table 1 
compd R1 R2 R3 KiCB1  nM  mouse 
KiCB2 
 nM  mouse 
KiCB1/KiCB2 
KiCB1 
 nM 
human 
KiCB2 
 nM  
human 
 
KiCB1/KiCB2
6 benzyl 4-methylcyclohexyl methyl NT NT NT 
   
7 p-fluorobenzyl 4-methylcyclohexyl methyl 8.7±1.6 1.4±0.1 6 5.6 0.79 7 
8 o-fluorobenzyl 4-methylcyclohexyl methyl 37.5±5.4 8.4±0.3 4 56 7.9 7 
9 benzyl cycloheptyl methyl 143.2±9.1 5.1±1.3 28    
10 p-fluorobenzyl cycloheptyl methyl 4.3±0.6 1.0±0.1 4.3    
11 o-fluorobenzyl cycloheptyl methyl 149.4±1.8 13.4±4.7 11    
12 1-ethyl-4-phenylpip cyclohexyl methyl >1000 >1000 
    
13 phenethyl cyclohexyl methyl >1000 16.3±1.2 >62    
14 p-methoxybenzyl cyclohexyl methyl >1000 35.8±2.1 >28 
   
21 ethylmorph cyclohexyl Cl >1000 25 >40    
22 benzyl cyclohexyl Cl 463.6±1.1 24.6±4.7 19    
23 p-fluorobenzyl cyclohexyl Cl 495.0±39.4 21.4±1.0 23    
24 o-fluorobenzyl cyclohexyl Cl 171.2±12.3 18.1±2.7 9.5    
25 ethylmorph 4-methylcyclohexyl Cl >1000 40.5±7.7 >25 
   
27 ethylmorph cyclohexyl F    >1000 13 >76.9 
28 benzyl cyclohexyl OCH3    560 11 51 
30 ethylmorph cyclohexyl N(CH3)2    >5600 94 >59.4 
32 p-fluorobenzyl cyclohexyl H 384.1±25.3 13.0±1.4 29    
33 benzyl cyclohexyl H >1000 48.6±12.0 >21    
34 ethylmorph cyclohexyl H >1000 67.2±11.6 >15    
36 o-fluorobenzyl cyclohexyl o-F-benzyl NT NT NT 
   
47 ethylmorph cyclohexyl H    NT NT  
48 benzyl cyclohexyl H    560 79 7 
49 ethylmorph cyclohexyl Cl    >1000 38 >26 
50 benzyl cyclohexyl OCH3    170 79 2.1 
51 ethylmorph cyclohexyl OCH3    2920 79 37 
52 benzyl cycloheptyl H    17 6.4 2.6 
53 ethylmorph cycloheptyl H    290 28 10.3 
54 benzyl cyclohexyl Cl    NT NT  
58 o-fluorobenzyl cyclohexyl methyl >1000 >1000     
59 ethylmorph 4-methylcyclohexyl methyl >1000 >1000 
    
60 benzyl cyclohexyl methyl >1000 >1000     
66 benzyl cyclohexyl H    620 790 0.78 
67 benzyl cyclohexyl Cl    560 1640 0.34 
68 ethylmorph cyclohexyl H    >5600 >7900 ----- 
69 ethylmorph phenyl H    2800 2280 1.2 
70 ethylmorph cyclohexyl Cl    NT NT ----- 
74 benzyl cyclohexyl NH2    5600 7900 0.7 
Win55212-
2 
      21 2.1 10 
HU-210       0.18 0.15 1.2 
AM630       840 36 23 
ACEA       5.3 95 0.06 
JWH-130       680 3 227 
SR141716A       16 1640 0.01 
SR144528       >50000 5.4 ----- 
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CB1 receptor affinity 
The results reported in Table 1 show that some of the compounds characterized by the 
presence in position 1 of orto or  para-fluorobenzyl  group possess an interesting affinity at 
the CB1 receptor. In particular, the 1,8-naphthyridine derivatives 7, 8, and 10 exhibit a 
considerable affinity but are not selective for this receptor. The other compounds showed very 
low affinity at this receptor. 
 
CB2 receptor affinity 
The results obtained indicate that, the N-benzyl-1,8-naphthyridine derivatives possess a higher 
affinity than the N-ethylmorpholino derivatives, as is clear from a comparison of compounds 
7-11, 14, 22-24, 28, 32-33 and 36,  with 21, 25, 27, 30 and 34. For the N-benzyl- 1,8-
naphthyridine derivatives (7-11, 14, 22-24, 28, 32-33), the presence of an atom of fluorine on 
the benzyl increases the affinity, above all if the substitution is in the para position. In 
particular, the p-fluorobenzyl-1,8-naphthyridine derivatives 7 (Ki =1.4 nM and Ki =0.79 nM 
determined from mouse and human respectively) and 10 (Ki =1.0 nM) proved to be the 
compounds with the highest affinity in this series. Furthermore, the N-phenethyl-1,8-
naphthyridine derivative 13 and the N-p-methoxybenzyl-1,8-naphthyridine derivative 14 
showed a good affinity, with a Ki of 16.3 nM and Ki of 35.8 nM respectively. In contrast, the 
compound bearing a 1-ethyl-4-phenylpiperazinyl group in position 1 of the naphthyridine 
nucleus (12) possesses a very low affinity, with a Ki value greater than 1000. 
Furthermore, the substitution of the methyl group in position 7 of the 1,8-naphthyridine 
nucleus with an atom of chlorine or fluorine, or with methoxy group, or dimethylamino group, 
or the lack of any substituent in the same position (21-25, 27-30, 32-34), generally determines 
the maintenance or an increase in the affinity (except for compounds 23 and 33, which 
showed a 4-fold and 5-fold decrease in affinity compared with the methyl analogues78). 
Compounds 47-54 in which the naphthyridin-4-one system was substituted by the quinoline-
4-one, possess a good affinity with Ki value <80nM. However this affinity is lower than one 
of the corresponding 1,8-naphthyridine derivatives, as is clear from a comparison of  48-50, 
with 21, 28 and 33. 
The 4-hydroxy-1,2,3,4-tetrahydro-1,8-naphthyridine derivatives 58-60 exhibit a poor affinity 
toward the CB2 receptor, with Ki values greater than 1000. 
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The compounds characterized by the 2H-pyrazolo[4,3-c]quinolin-3(5H)-one central scaffold 
(66-70), showed a very low affinity toward both CB receptor subtypes. 
The shifting of the carboxamide group from position 3 to position 2 (compound 74) of the 
heterocyclic nucleus together with the substitution of the methoxy group in position 7 with the 
amino group causes a drastic decrease of affinity toward both cannabinoid receptors, as 
confirmed by a comparison of this compound (74)  with compound 28. 
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Test for CB2 Functionality 
 
To assess the functionality of the studied compounds at CB2 receptors, functional studies on 
human basophils were performed. Activation of CB2 receptors is known to down-regulate the 
immunological activation of guinea pig mast cells and human basophils.86,87 N-Cyclohexyl-1-
benzylquinolin-4(1H)-on-3-carboxamide (48) and N-cyclopentyl-7-methyl-1-(2-morpholin-4-
ylethyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide,78 which is structurally analogous to the 
1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives, were used for functional studies. 
Human basophils, pretreated with these compounds (1 nM to 1 μM, 30 min of preincubation, 
37 °C), showed a reduced expression of CD203c in response to immunological stimulation 
(anti-IgE 1 íg/mL, 30 min, 37 °C). The inhibition was reversed by the selective CB2 antagonist 
SR 144528 (SR, 100 nM, 30 min of preincubation, 37 °C) but not by AM251 (AM, 100 nM, 
30 min of preincubation, 37 °C), a selective CB1 antagonist.  
These results show that compounds 48 and N-cyclopentyl-7-methyl-1-(2-morpholin-4-
ylethyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide,78 exert a CB2-mediated inhibitory action 
on immunological human basophil activation. Furthermore, we hypothesize that  the quinolin-
4-(1H)-on-3-carboxamide 47, 49-54 and the 1,8-naphthyridin-4(1H)-on-3-carboxamide 
derivatives 6-14, 21-28, 30, 32-34 and 36 possess the same kind of activity. This result 
indicated that these compounds behaved as CB2 receptor agonist. 
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Molecular Modeling 
 
The synthesized ligands were docked using AUTODOCK 3.0,88 in the CB1 and CB2 receptor 
models prepared by molecular modeling.77  
Figure 18 (a, b) shows the docking of compound 28 into both receptors; in the CB1 receptor 
model, the naphthyridine and the cyclohexyl ring predominantly interact in the lipophilic 
pocket delimited by W5.43(279), T5.47(283), W6.48(356), L6.52(360), and V6.56(364), 
while the benzyl group is positioned in a secondary lipophilic pocket formed by L3.26(190), 
P4.60(251), and L4.61(252) (figure 18). 
In the CB2 receptor model, the benzyl ring of the ligand interacted similarly to the CB1 
receptor in the lipophilic pocket delimited by L3.27(108), P4.60(168) and L4.61(169) (figure 
18) whereas the naphthyridine ring was rotated about 130° (counterclockwise sense from the 
extracellular point of view) and mainly interacted with W5.43(194), M6.55(265), and 
L6.60(269). Furthermore the methoxy substituent formed an H bond with the non-conserved 
S6.58(268) (substituted by D366 in the CB1 receptor) and the cyclohexyl group, beyond the 
lipophilic interactions with T3.37(118), W5.43(194), and W6.48(258), feels the effect of a 
strong interaction with F5.46(197), which is a non-conserved residue (V282 in the CB1) 
(figure 18). The interactions with S6.58(268) and F5.46(197), together with the different 
disposition of the naphthyridine ring, could be the reason for the CB2 versus CB1 selectivity of 
this ligand.  
The docking of compound 10 showed that the cycloheptyl substituent was directed toward the 
intracellular side of the receptor, interacting with W5.43(194) and F5.46(197) (see Figure 18 
c). As for the p-F-benzyl group, it interacted in a lipophilic pocket formed by L3.27(108), 
P4.60(168), and L4.61(169), and the fluorine atom formed an H bond with S3.31(112). 
 
 
         
 
 
 
 
 
 
                                    a                                                                            b                                          
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                                                                               c       
Figure 18 
 
The docking of the inactive compounds 58-60 revealed that the lack of planarity determines a 
different position of the central lipophilic core, determining weaker interactions with the 
receptor. As shown in Figure 19, the central core of 60, compared with the position of the 
naphthyridine ring of N-cyclohexyl-7-methyl-1-benzyl-1,8-naphthyridin-4(1H)-on-3-
carboxamide,78 that was shifted further way from TM3 and directed toward TM5, determining 
weaker interactions with M6.55(265) and L3.27(107); furthermore, this arrangement 
determined a weaker interaction of the cyclohexyl ring with F5.46(197). From this 
consideration we can confirmed the hypothesis about the fundamental role of the presence of a 
planar pseudocycle with the naphthyridine nucleus obtained by an intramolecular H bond 
between the carbonylic oxygen and the amidic NH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 
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As shown in Figure 20, compound 67 disposition in the CB1 binding, site very similar to the 
one observed for compound 28, with the same lipophilic interactions, in agreement with the 
very similar CB1 affinity value. On the other hand, in the CB2 binding site, the benzyl group 
was directed toward S6.58(268) and lost lipophilic interactions inside the pocket delimited by 
L3.27(108), P4.60(168) and L4.61(169), which explains its low CB2 affinity.     
 
                                                                                        
 
 
 
 
 
 
 
Figure 20 
 
These analysis suggested that the preservation of good CB2/CB1 selectivity and the 
improvement of the CB2 affinity seemed to require the presence of a lipophilic or aromatic R1 
substituent with an H bond acceptor atom capable of interacting in the CB2 receptor with the 
nonconserved S3.31(112), belong to the second lipophilic pocket of the receptor. The 
substitution of the carboxycyclohexylamide group in position 3 of the 1,8-naphthyridine 
nuclear with a carboxycycloheptylamide group and 4-methylcarboxycyclohexylamide group 
determine an increase in the affinity toward the CB2 receptor. Infact these groups  interact 
with the residues W5,43(194) and F5,46(197), belong to the first lipophilic pocket of the 
receptor (TM5).  
The presence in position 7 of the heterocyclic nucleus of an H bond acceptor atom or goup 
(chlorine, fluorine or methoxyl group) capable of interacting with the nonconserved residue 
S6.58(268) in the CB2 receptor seemed to be one of the reasons for the high selectivity value. 
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INTRODUCTION OF EXPERIMENTAL PART 
  
PART 2 
 
Successful I synthesized new 1,8-naphthrydine of general structure G characterized by the 
presence of a carbonilic group in position 2, to verify  if this shift could be create a new 
interaction of binding site receptor.  
 
 
 
 
           
                                                                            G 
 
The synthesis of  compounds of general structur G is outlined in Schemes 10. 
The heating of  2-aminopyridin-3-carboxaldheyde with ethyl malonate and a few drops of 
piperidine at 90°C for 4h  afforded the ethyl 2-oxo-1,2-dihydro-1,8-naphthyridin-3-
carboxylate derivative 75.90 
The treatment of ethyl ester 75  with the appropriate amine in sealed tube for 24 h at 120°C 
provided the desired carboxamide derivatives 76-81. 
Successful the treatment of carboxamide derivatives 76-81 in anhydrous DMF with NaH  and 
than with the suitable benzylchloride or aryl-alkylchloride or 4-(2-chloroethyl)-morpholine 
provided the desired 1,8-naphthyridin-2-one derivatives 82-93 (Scheme 10). 
 
Moreover new 1,8-naphthrydine and quinoline derivatives characterized by  the presence of a 
carbonilic group  in positions 4 and 2, were synthesized to verify the effect of a further 
carbonilic group on the affinity and on the selectivity toward both CB receptor subtypes.  
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The synthesis of these compounds is outlined in Scheme 11. The esterification  of 2-
aminonicotinic acid with concentrated H2SO4 and CH3OH at 80°C for 7h gave the methyl 2-
aminonicotinate 94. The heating of  compound 94 with EMME at 80°C for 6h gave the 
derivative 1,8-naphthrydin-2,4-dione 95. The reaction of 95 with cyclohexylamine at 120°C 
for 24h  in sealed tube provided the carboxamide derivative 96, which for  treatment in 
anhydrous DMF with NaH and then with the suitable benzyl chloride or 4-(2-chloroethyl)-
morpholine at 50 °C for 24h provided the desired compounds 97 and 98. 
The synthesis of  quinoline compounds is reported in Scheme 12. The reaction of aniline with 
the triethyl methanetricarboxylate in microwave in open vessel at 210°C, P 200 W, p 200 psi 
for 15 min gave the carboxamide derivative 99. 
The  compounds 100 and 101 were obtained from 99 by similar condition above reported for 
the preparation of 97 and 98. 
 
 Finally to verify the importance of the presence of both aromatic rings in the central 
lipophilic bicyclic core, I have synthesized the pyridin compounds with general structure I.  
 
 
 
                                                                                                                                          
 
 
 
               
The monocyclic derivatives were obtained as reported in Scheme 13, starting from 2-
hydroxynicotinic acid which by reaction  with concentrated H2SO4 and CH3OH at 80°C in 
microwave, at 200 W, 100 psi and for 55 min.  
The heating of ester 102 with the appropriate amine provided the carboxamide derivatives 
103-105 which were tranformed  in to desired compounds 106-112 by reaction with NaH and 
the suitable chloro derivatives at room temperature.  
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Results and discussion 
 
CB1 and CB2 affinity 
 
Affinities at CB1 and CB2 receptors for all these  compounds (82-93, 97, 98, 100, 101 and 
106-112) were tested using  membranes from HEK-293 cells transfected with either the 
human CB1 and CB2 receptors. 
The CB1 and CB2 receptor binding assay results for these new compounds are summarized in 
Table 2. The Ki values of WIN-55,212-2, HU-210, AM630, JWH-133, ACEA, SR141716A 
and SR144528 are also included in the table as reference compounds for the CB1 and CB2 
cannabinoid receptors. 
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     compd R1 R2 
Ki CB1 
 nM 
human
Ki CB2 
nM 
human 
KiCB1/KiCB2 
82 benzyl cyclohexyl 560 31 18 
83 p-fluorobenzyl cyclohexyl 56 2.2 25.5 
84 butyl cyclohexyl 5600 70 80 
85 benzyl 4-methylcyclohexyl >1000 3.5 >285.7 
86 ethylmorph 4-methylcyclohexyl 1000 1.9 526.3 
87 ethylmorph cyclohexyl 560 7.9 70.9 
88 benzyl β-phenylethyl Non sol.   
89 benzyl 4-fluoro-phenylethyl >1000 190 5.3 
90 benzyl cycloheptyl 960 22 43.6 
91 p-fluorobenzyl 
4-
methylcyclohexyl 96 0.9 106.7 
92 p-fluorobenzyl cycloheptyl 9.6 0.7 13.7 
93 ethylmorph cycloheptyl 18 3 6 
97 Ethylmorph cyclohexyl NT NT  
98 benzyl cyclohexyl 560 79 7.1 
100 Ethylmorph phenyl NT NT  
101 benzyl phenyl 5600 200 2.8 
106 benzyl cyclohexyl 800 200 4 
107 ethylmorph cyclohexyl n.d. 7900  
108 p-fluorobenzyl cycloheptyl 40 7.9 5 
109 p-fluorobenzyl cyclohexyl 70 20 3.5 
110 benzyl cycloheptyl 56 7.9 7 
111 ethylmorph cycloheptyl 950 79 12 
112 p-fluorobenzyl 
4-
methylcyclohexyl NT NT  
Win552122   21 2.1 10 
HU-210   0.18 0.15 1.2 
AM630   840 36 23 
ACEA   5.3 95 0.06 
JWH-130   680 3 227 
SR141716A   16 1640 0.01 
SR144528   >50000 5.4 ----- 
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CB1 receptor affinity 
The results reported in Table 2 show that some of the compounds characterized by the 
presence in position 1 of p-fluorobenzyl or ethylmorpholin group possess an interesting 
affinity at the CB1 receptor in particular compounds 83, 91-93 and 108-110 showed a Ki value 
<100 nM. The other compounds showed very low affinity at this receptor. 
 
CB2 receptor affinity 
The new compounds,  1,8-naphthrydin-2-one 82-93 generally showed a high affinity and 
selectivity  for CB2 receptor. Infact compounds 83, 85-87,  and 91-93 showed a KiCB2< 10 
nM, in particular compounds 91 and 92 showed a subnanomolar affinities. Some of these   
compounds possess an important selectivity on CB2 receptor. In particular compounds  85, 86 
and 91 showed a  Ki(CB1)/Ki(CB2) of >285.7, 526.3 and 106.7 respectively. 
From these results it’s clear that the 1,8-naphthrydin-2-one 82-93 exhibit a higher affinity and 
selectivity for CB2 receptor than the corresponding 1,8-naphthrydin-4-one.  
The compound 98 characterized by the presence of two carbonilic groups possess an 
interesting affinity for the CB2 receptor (Ki= 79nM) with a low selectivity. 
Regards the new monocyclic derivatives the compounds 108 and 110 showed a remarkable 
affinity for CB2 receptor. (Ki= 7.9 nM) The compounds 109 and 111 showed a relatively good 
affinity (Ki CB2 20 and 79 nM respectively.)  In the light of these results it is clear that the 
pyridine compounds (106-112)  represent a new classes of heterocyclic derivatives as ligands 
of  CB2 cannabinoid receptor. 
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Molecular Modeling 
 
Studies of automated docking have showed that the compounds 1,8-naphthyridin-2-one 
analogously to compounds 1,8-naphthyridin-4-one form an intramolecular hydrogen bond 
between the carbonilic oxygen and the amidic’s carbonolic form a pseudocycle planar to 
heterocycle ring. (structure L); moreover the amidic’s carbonilic form a hydrogen bond with 
residual of Thr 114 (T3.37) that is not conservated in CB1 receptor (figure 21). 
 
 
 
 
                                                                     
                                                                   L         
 
                                                              
 
 
 
 
 
 
 
 
 
 
Figure 21 
 
 The results obtained for these compounds suggested that the good CB2/CB1selectivity and the 
improvement of the CB2 affinity respect of the analogues compounds 1,8-naphthyridin-4(1H)-
one  seemed to be produced by  the presence of a carbonilic group in position 2 that determine 
a different rearrangement of  all molecule  into the receptor, giving an interaction between  the 
amidic’s carbonilic with the  residue of T3.37 (T114) in the CB2 receptor.(see figure 22) 
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Figure 22 
 
Finally,  the virtual screening in the CB2 receptor of monocyclic compounds (106-112) 
revealed that these ligands seem interacting like the 1,8-naphthyridin-2-one in the binding 
pocket of the receptor conserving the same interactions. (see figure 23)  
 
                                       
 
 
 
 
 
 
 
               
 
 
Docking of monocyclic derivatives.                       Docking of naphthyridine derivatives. 
 
 
Figure 23 
 
 
 
 
 
 53
Antinociceptive effects 
 
 
 The N-Cyclohexyl-7-methoxy1-(2-morpholin-4-yl-ethyl)-1,8-naphthyridin-4(1H)-on-3-
carboxamide (28) which showed a high CB2 affinity and selectivity (Ki = 11 nM, 
Ki(CB1)/Ki(CB2) = 51) was tested to determine antinociceptive effects in the mouse hot-plate 
test.91,92 Furthermore, mouse motor coordination was evaluated in the rotarod test.93,94 
Compound 28 exhibited an antinociceptive effect at the dose of 50 mg kg-1 p.o. in the mouse 
hot-plate test 15 and 30 min after administration. 
 
Table3. Effect of AM630 on antinociception induced by derivative 28 in the mouse hot-plate test 
Treatment 1 
p.o. 
Treatment 2 
p.o. 
N° of 
mice Licking latency (s) 
   After treatment 
   
Before pre 
treatment 15 min 30 min 45 min 
CMC CMC 12 14.8±0.6 15.5±0.7 16.8±0.6 14.7±0.5 
CMC AM630 
0.6 mg kg-1 14 15.2±0.4 16.6±0.6 18.0±0.4 16.3±0.4 
CMC 28 
10 mg kg-1 10 14.5±0.8 17.1±0.9 18.5±1.0 16.7±0.6 
CMC 28 
30 mg kg-1 10 14.4±0.6 16.6±0.8 19.5±1.0 17.4±0.6 
CMC 28 
50 mg kg-1 13 15.1±0.5 19.2±0.6* 22.5±0.9* 18.2±0.7 
28 
50 mg kg-1 
AM630 
0.6 mg kg-1 10 16.2±0.7 18.1±0.7 19.2±0.4^ 17.6±0.6 
          * P<0.05 vs. CMC-treated mice; ^P<0.05 vs 28-treated mice. AM-630 and 28 were administered simultaneously. 
 
 
Treatment with AM630, a selective CB2 antagonist,95 at the dose of 0.6 mg kg-1 p.o. partially 
reverted the antinociceptive effect of 28 in correspondence of its peak of efficacy. 
The dose of AM630 employed (0.6 mg kg-1 p.o.) did not modify by itself mouse pain 
threshold in the presence of a thermal stimulus and represents the minimal dose able to reduce 
the antinociception induced by compound 28 
It is interesting to note this compound at the antinociceptive dose did not modify mouse motor 
coordination evaluated in the rotarod test (see Table 4). 
 
Table 4. Effect of 28 on motor coordination in the mouse rota-rod test 
  N° of  falls 
Treatment 
p.o. 
N° of 
mice After treatment 
  
Before 
treatment 15 min 30 min 45 min 
CMC 12 3.3±0.2 0.8±0.2 0.3±0.2 0.2±0.2 
28 
50 mg kg-1 13 4.0±0.7 0.7±0.2 0.2±0.2 0.2±0.2 
 
 
 
 54
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme of synthesis 
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                                                                SCHEME 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and Conditions: (i) EMME, 110°C, 2h; (ii) Dowtherm A, 1h; 
                                             (iii) R2NH2, 120°C, 24h; (iv) DMF, NaH, R1Cl. 
 
                                                           
 
compd R1 R2 
3 H 4-methylcyclohexyl 
4 H cycloheptyl 
5 H cyclohexyl 
6 benzyl 4-methylcyclohexyl 
7 p-fluorobenzyl 4-methylcyclohexyl 
8 o-fluorobenzyl 4-methylcyclohexyl 
9 benzyl cycloheptyl 
10 p-fluorobenzyl cycloheptyl 
11 o-fluorobenzyl cycloheptyl 
12 1-ethyl-4-phenylpip cyclohexyl 
13 phenethyl cyclohexyl 
14 p-methoxybenzyl cyclohexyl 
NH3C N
H
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O
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SCHEME 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and Conditions: (i) CH3COCl, r.t. 2h; (ii) Dowtherm A, EMME, 200°C, 15 min. 
                                             (iii) R2NH2, 120°C, 24h. 
 
 
 
 
 
 
 
compd R2 
17 4-methylcyclohexyl 
18 cyclohexyl 
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Reagents and Conditions: (i) thetrafluoroboric acid, NaNO2, r.t., 1h 30 min; (ii) DMF, NaH, 2-                     
chloroethylmorpholine; (iii)NaNO2, HCl, 40°C, 3h; (iv)DMF, NaH, R1Cl; 
                                                  (v) CH3ONa, 80°C, 5h 30 min.   
 
 
compd R1 R2 R3 
19 H 4-methylcyclohexyl Cl 
20 H cyclohexyl Cl 
21 ethylmorph cyclohexyl Cl 
22 benzyl cyclohexyl Cl 
23 p-fluorobenzyl cyclohexyl Cl 
24 o-fluorobenzyl cyclohexyl Cl 
25 ethylmorph 4-methylcyclohexyl Cl 
28 benzyl cyclohexyl OCH3
17, 18
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Reagents and Conditions: (i) dimethylamine,120°C, 24h; (ii) DMF, NaH, 2-chloroethylmorpholine;  
(iii) MeOH, H2/Pd, r.t., 3h; (iv) DMF, NaH, R1Cl. 
 
 
 
 
compd R1 R2 
32 p-fluorobenzyl cyclohexyl 
33 benzyl cyclohexyl 
34 ethylmorph cyclohexyl 
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Reagents and Conditions: (i) NaNO2, H2SO4; (ii) DMF, NaH, o-fluorobenzylchloride 
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Reagents and Conditions: (i) EMME, 130°C, 5h; (ii) Dowtherm A, reflux, 1h; (iii) R2NH2, 120°C, 24h; 
                                             (iv) DMF, NaH, R1Cl. 
 
 
 
 
compd R1 R2 R3 
37 H ---- H 
38 H ---- Cl 
39 H ---- OCH3 
40 H ---- H 
41 H ---- Cl 
42 H ---- OCH3 
43 H cyclohexyl H 
44 H cyclohexyl Cl 
45 H cyclohexyl OCH3 
46 H cycloheptyl H 
47 ethylmorph cyclohexyl H 
48 benzyl cyclohexyl H 
49 ethylmorph cyclohexyl Cl 
50 benzyl cyclohexyl OCH3 
51 ethylmorph cyclohexyl OCH3 
52 benzyl cycloheptyl H 
53 ethylmorph cycloheptyl H 
54 benzyl cyclohexyl Cl 
NR3
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SCHEME 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and Conditions: (i) EtOH ass., NaBH4. 
 
 
 
 
 
compd R1 R2 R3 
55 o-fluorobenzyl cyclohexyl methyl 
56 ethylmorph 4-methylcyclohexyl methyl 
57 benzyl cyclohexyl methyl 
58 o-fluorobenzyl cyclohexyl methyl 
59 ethylmorph 4-methylcyclohexyl methyl 
60 benzyl cyclohexyl methyl 
N NH3C
O
R1
N
R2
O
H
58-60
55-57
i
N NH3C
OH
R1
N
R2
O
H
 62
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                        
 
 
                                       
 
 
 
 
 
 
 
 
                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and Conditions: (i) POCl3, 120°C, 14 min; (ii) R2NHNH2, p-xilene 150°C, 13h;  
(iii) DMF, NaH, R1Cl. 
 
compd R1 R2 R3 
39 H ---- H 
40 H ---- Cl 
61 H ---- H 
62 H ---- Cl 
63 H cyclohexy H 
64 H phenyl H 
65 H cyclohexyl Cl 
66 benzyl cyclohexyl H 
67 benzyl cyclohexyl Cl 
68 ethylmorph cyclohexyl H 
69 ethylmorph phenyl H 
70 ethylmorph cyclohexyl Cl 
N
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Reagents and Conditions: (i) acethylendicarboxylic acid dimethyl ester, 180°C, 24h; (ii)Dowtherm A reflux,      
1h; (iii) cyclohexylamine 120°C, 24h; (iv) DMF, NaH, benzylchloride. 
72
73
74
N N
O
O
N
H
H2N
N N
O
H O
N
H
H2N
N NAcNH
O
H O
OCH3
N NHAcH2N
N N
H
AcNH
H O
OCH3
OCH3
O
15
71
         SCHEME 9
iv
iii
ii
i
 64
 
 
SCHEME 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and Conditions: (i) EMME, 90°C, 24h; (ii) R2NH2, 120°C, 24h; (iii) DMF, NaH, R1Cl. 
 
compd R1 R2 
76 H cyclohexyl 
77 H 4-methylcyclohexyl 
78 H 2(2-aminoethyl)pyridine 
79 H β-phenylethyl 
80 H 4-fluoro-phenylethyl 
81 H cycloheptyl 
82 benzyl cyclohexyl 
83 p-fluorobenzyl cyclohexyl 
84 butyl cyclohexyl 
85 benzyl 4-methylcyclohexyl 
86 ethylmorph 4-methylcyclohexyl 
87 ethylmorph cyclohexyl 
88 benzyl β-phenylethyl 
89 benzyl 4-fluoro-phenylethyl 
90 benzyl cycloheptyl 
91 p-fluorobenzyl 4-methylcyclohexyl 
92 p-fluorobenzyl cycloheptyl 
93 ethylmorph cycloheptyl 
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SCHEME 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and Conditions: (i) MeOH, H2SO4, 80°C, 7h; (ii) EMME, Na, EtOH, reflux, 6h. (iii) cyclohexylamine 
120°, 24h; (iv) DMF, NaH, R1Cl, 50°C, 24h. 
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SCHEME 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                Reagents and Conditions: (i) MW, open vessel, 210°C, 15 min, 200W,;(ii) DMF, NaH, R1Cl. 
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101 benzyl 
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SCHEME 13 
 
                                                                                                      
 
 
 
 
 
 
 
 
 
      
 
                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
                                                                             
 
 
 
 
 
Reagents and Conditions: (i) MW, MeOh, H2SO4, 200W, 100psi, 80°C, 55 min; (ii) R2NH2, in  MW for  
compound 103, in oil bath for compounds 104 and 105; (iii)   DMF, NaH, R1Cl, r.t.. 
 
 
 
compd R1 R2 
103 H cyclohexyl 
104 H cycloheptyl 
105 H 4-methylcyclohexyl 
106 benzyl cyclohexyl 
107 ethylmorph cyclohexyl 
108 p-fluorobenzyl cycloheptyl 
109 p-fluorobenzyl cyclohexyl 
110 benzyl cycloheptyl 
111 ethylmorph cycloheptyl 
112 p-fluorobenzyl 4-methylcyclohexyl 
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Melting points were determined on a Kofler hot stage apparatus and are uncorrected. IR 
spectra in Nujol mulls were recorded on an ATI Mattson Genesis series FTIR spectrometer. 
1H NMR spectra were recorded with a Bruker AC-200 spectrometer in δ units from TMS as 
an internal standard. Mass spectra were obtained with a Hewlett-Packard MS system 5988. 
Elemental analysis results (C, H, N) were within (0.4% of theoretical values and were 
performed on a Carlo Erba elemental analyzer model 1106 apparatus. 
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Experimental part scheme 1 
 
2-(N-diethylmalonate)-amino-6-methylpyridine 1 
A mixture of 0.1 mmol of 2-amino-6-methylpyridine and 0.1 mmol of EMME was heated at 
110°C for 2 h. After cooling the mixture solidify to give the diethyl esther 1. 
Yield: 98%; mp: 105-107° C;  
 
ethyl-7-methyl-4-oxo-1,8-naphthyrydin-3-carboxylate 2 
A mixture of 0.018 mol of  2-(N-diethylmalonate)-amino-6-methylpyridine and ml 25 of 
Dowtherm A was heated at reflux for 30’. After cooling the solid obtained was washed with 
petroleum ether and collected by filtration. 
Yield: 67%; mp: 233-235°C; 1H NMR: DMSO δ 8.44 (s, 1H, H2), 8.38 (d, 1H, H5), 7.35 (d, 
1H, H6), 4.20 (q, 2H, CH2), 2.58 (s, 3H, CH3), 1.26 (t, 3H, CH3).  
 
General procedure for the synthesis of 7-methyl-1,8-naphthyridin-3-carboxyamide 
derivatives 3-5  
A mixture of 1 mmol of 7-methyl-1,8-naphthyridin-4(1H)-on-3-carboxylic acid ethyl ester and 
10 mmol of the appropriate amine was heated in sealed tube at 120 °C for 24 h. After cooling, 
the reaction mixture was treated with ethyl ether to give a solid residue which was collected 
by filtration and purified by crystallization.  
 
7-Methyl-N-(4-methylcyclohexyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide 3 
Yield 56%; mp 260–270 °C (cyclohexane); 1H NMR: DMSO δ 10.55, 10.16 (2d, 1H, NH), 
8.75, 8.74 (2s, 1H, H2), 8.48, 8.43 (2d, 1H, H5), 7.29, 7.25 (2d, 1H, H6), 4.10 (m, 1H, H1′), 
3.70 (m, 1H, H4′), 2.62 (s, 3H, CH3), 2.49 (s, 3H, CH3), 1.87–1.68 (m, 8H, cyclohexyl). Anal. 
C17H21N3O2 C, H, N.  
 
N-Cycloheptyl-7-methyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 4 
Yield 70%; mp 270–272 °C (ethyl acetate); 1H NMR: DMSO δ 9.93 (d, 1H, NH), 8.61 (s, 1H, 
H2), 8.49 (d, 1H, H5), 7.42 (d, 1H, H6), 4.15 (m, 1H, CH), 2.62 (s, 3H, CH3), 1.85–1.56 (m, 
12H, cycloheptyl). Anal. C17H21N3O2 C, H, N. 
 
N-Cyclohexyl-7-methyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 5 
Yield 85%; mp 302–304 °C (ethyl acetate); 1H NMR: DMSO δ 10.31 (d, 1H, NH), 8.74 (s, 
1H, H2), 8.43 (d, 1H, H5), 7.25 (d, 1H, H6), 3.90 (brs, 1H, CH), 2.57 (s, 3H, CH3), 1.81–1.06 
(m, 10H, cyclohexyl). Anal. C16H19N3O2 C, H, N.  
 
 
General Procedure for the Synthesis of N1-Substituted 1,8-Naphthyridine Derivatives 6-
14 
An amount of 1.2 mmol of NaH was added to a solution of 1 mmol of carboxamide 
derivatives 3-5 in 10 mL of dry N,Ndimethylformamide. After 1 h, the appropriate chloride (1 
mmol) was added and the mixture was stirred for 24 h at room temperature for compounds 6-
11, 12, or at 50 °C for compounds 13, 14. The reaction mixture, after cooling was treated with 
water, and the precipitate formed was collected by filtration.  
 
N-(4-Methylcyclohexyl)-1-benzyl-7-methyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 6.  
Yield 80%; mp 239-241 °C (crystallized from ethyl acetate); MS m/z 389 (M+); 1H NMR: 
δ 10.20, 9.75 (2d, 1H, NH), 9.08, 9.06 (2s, 1H, H2), 8.52, 8.60 (2d, 1H, H5), 7.48 (d, 1H, H6), 
7.33 (m, 5H, Ar), 5.80 (s, 2H, CH2), 4.12, 3.69 (2m, 1H, CH), 2.63 (s, 3H, CH3), 2.20-0.86 
(m, 12H, cyclohexyl + CH3). Anal. C24H27N3O2 C, H, N. 
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N-(4-Methylcyclohexyl)-1-(p-fluorobenzyl)-7-methyl-1,8-naphthyridin-4(1H)-on-3-
carboxamide 7. 
Yield  66%; mp 167-169 °C (crystallized from n-hexane); MS m/z 407 (M+); 1H NMR: δ 
10.18, 9.77 (2d, 1H, NH), 9.12, 9.10 (2s, 1H, H2), 8.59, 8.52 (2d, 1H, H5), 7.50 (m, 3H, Ar + 
H6), 7.16 (m, 2H, Ar), 5.77 (s, 2H, CH2), 4.18, 3.70 (2m, 1H, CH), 2.65 (s, 3H, CH3), 1.98-
0.86 (m, 12H, cyclohexyl + CH3). Anal. C24H26FN3O2 C, H, N. 
 
N-(4-Methylcyclohexyl)-1-(o-fluorobenzyl)-7-methyl-1,8-naphthyridin-4(1H)-on-3-
carboxamide 8.  
Yield 60%; mp 183-185 °C (crystallized from n-hexane); MS m/z 407 (M+); 1H NMR: δ 
10.18, 9.77 (2d, 1H, NH), 9.09, 9.07 (2s, 1H, H2), 8.58, 8.52 (2d, 1H, H5), 7.46 (d, 1H, H6), 
7.36-7.14 (m, 4H, Ar), 5.81 (s, 2H, CH2), 4.15, 3.70 (2m, 1H, CH), 2.61 (s, 3H, CH3), 2.00-
0.86 (m, 12H, cyclohexyl + CH3). Anal. (C24H26FN3O2) C, H, N. 
 
N-Cycloheptyl-1-benzyl-7-methyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 9.  
Yield 58%; mp 198-200 °C (crystallized from cyclohexane); MS m/z 389 (M+); 1H NMR: δ 
9.88 (d, 1H, NH), 9.07 (s, 1H, H2), 8.55 (d, 1H, H5), 7.48 (d, 1H, H6), 7.33 (m, 5H, Ar), 5.79 
(s, 2H, CH2), 4.15 (m, 1H, CH), 2.64 (s, 3H, CH3), 1.85-1.39 (m, 12H, cycloheptyl). Anal. 
C24H27N3O2 C, H, N. 
 
N-Cycloheptyl-1-(p-fluorobenzyl)-7-methyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 
10. 
 Yield 75%; mp 194-196 °C (crystallized from hexane); MS m/z 407 (M+); 1H NMR: δ 9.91 
(d, 1H, NH), 9.10 (s, 1H, H2), 8.55 (d, 1H, H5), 7.48 (m, 3H, Ar+H6), 7.16 (m, 2H, Ar), 5.77 
(s, 2H, CH2), 4.15 (m, 1H, CH), 2.64 (s, 3H, CH3), 1.85-1.39 (m, 12H, cycloheptyl). Anal. 
C24H26FN3O2 C, H, N. 
 
N-Cycloheptyl-1-(o-fluorbenzyl)-7-methyl-1,8-naphthyridin-4(1H)-on-3-carboxamid 
11.  
Yield 63%; mp 188-189 °C (crystallized from cyclohexane); MS m/z 407 (M+); 1H NMR: δ 
9.90 (d, 1H, NH), 9.07 (s, 1H, H2), 8.55 (d, 1H, H5), 7.46 (d, 1H, H6), 7.32-7.14 (m, 4H, Ar), 
5.81 (s, 2H, CH2), 4.15 (m, 1H, CH), 2.61 (s, 3H, CH3), 1.85-1.39 (m, 12H, cycloheptyl). 
Anal. C24H26FN3O2 C, H, N. 
 
N-Cyclohexyl-7-methyl-1-[2-(4-phenylpiperazin-1-yl)ethyl]-1,8-naphthyridin-4(1H)-on-
3-carboxamide 12.  
Purified by flash chromatography (ethyl acetate/hexane/triethylamine, 10:1:0.2), yield 0.120 
g, 25%; mp 147-149 °C (crystallized from hexane); MS m/z 473 (M+); 1H NMR: δ  9.87 (d, 
1H, NH), 8.94 (s, 1H, H2), 8.53 (d, 1H, H5), 7.46 (d, 1H, H6), 7.18 (m, 2H, Ar), 6.90-6.71 (m, 
3H, Ar), 4.70 (m, 2H, CH2), 3.80 (m, 1H, CH), 3.03 (m, 4H, piperazinyl), 2.73 (m, 2H, CH2), 
2.66 (s, 3H, CH3), 2.60 (m, 4H, piperazinyl), 1.85-1.08 (m, 10H, cyclohexyl). Anal. 
C28H35N5O2 C, H, N  
 
N-Cyclohexyl-7-methyl-1-phenethyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 13.  
Purified by flash chromatography (ethyl acetate/hexane, 2:3), yield 28%; mp 148-150 °C 
(crystallized from hexane); MS m/z 389 (M+); 1H NMR: δ  9.86 (d, 1H, NH), 8.85 (s, 1H, H2), 
8.54 (d, 1H, H5), 7.48 (d, 1H, H6), 7.24 (m, 5H, Ar), 4.76 (m, 2H, CH2), 3.90 (m, 1H, CH), 
3.10 (m, 2H, CH2), 2.69 (s, 3H, CH3), 1.85-1.23 (m, 10H, cyclohexyl). Anal. C24H27N3O2 C, 
H, N. 
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N-Cyclohexyl-7-methyl-1-(4-methoxybenzyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide 
14.  
Purified by flash chromatography (ethyl acetate/hexane, 2: 1), yield 70%; mp 170-172 °C 
(crystallized from hexane); MS m/z 405 (M+); 1H NMR: δ  9.90 (d, 1H, NH), 9.05 (s, 1H, H2), 
8.54 (d, 1H, H5), 7.47 (d, 1H, H6), 7.35 (d, 2H, Ar), 6.89 (d, 2H, Ar), 5.70 (s, 2H, CH2), 3.80 
(m, 1H, CH), 3.70 (s, 3H, OCH3), 2.67 (s, 3H, CH3), 1.90-1.30 (m, 10H, cyclohexyl). Anal. 
C24H27N3O3 C, H, N. 
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Experimental part scheme 2 
 
2-acetylamino-6-aminopyridine 15. 
To a mechanically stirred solution of 2 g (0.018 mol) of 2,6-diaminopyridine in 9 ml of 
dioxane was added at 5°C a solution of  0.43 ml (0.009 mol) of acethyl chloride and ml 1,5 of 
dioxane dropwise in 30 min.Succesfuld the reaction was stirring for 2 h at room temperature. 
The solid obtained was filtered and the dioxane obtained was evaporated to give a solid which  
was purificated by flash chromatography ( ethyl acetate). 
Yield: 34%; mp: 91-93° C; 1H NMR: DMSO δ 7.71 (s, 1H, NH), 7.32 (m, 2H, Ar), 6.15 (d, 
1H, Ar), 5.59 (s, 2H, NH2), 2.11 (s, 3H, CH3).  
 
 
7-acetamido-1,8-naphthyridin-4(1H)-on-3-carboxylic acid ethyl ester 16 
A mixture of 0.5 g of monoacetyl derivative 15 with ml 1 of EMME in 10 ml Dowtherm A at 
200°C for 15 mins. After cooling the solid obtained was collected by filtration and washed 
with petroleum ether and ethanol to gave a 7-acetamido-1,8-naphthyridin-4(1H)-on-3-
carboxylic acid ethyl ester 16. 
Yield: 78,55%; mp:298-300°C; 1H NMR: DMSO δ 12.05 (d, 1H, NH), 10.80 (s, 1H, Ar), 8.45 
(d, 1H, Ar), 8.13 (d, 1H, Ar), 4.22 (q, 2H, CH2), 2.18 (s, 3H, CH3), 1.26 (t, 3H, CH3). 
 
 
General procedure to the synthesis of the 7-Amino-N-substituted-1,8-naphthyridin-
4(1H)-on-3-carboxamide  17, 18. 
A mixture of 1,8-naphthyridine-3-carboxylic acid ethyl ester 1681 (0.276 g, 1 mmol) and 10 
mmol of suitable amine was heated in sealed tube at 120°C for 24 h. After cooling, the 
reaction mixture was treated with ethyl ether to give a solid residue, which was collected by 
filtration and purified by crystallization from ethyl acetate to obtain the compounds 17 and 18. 
 
N-(4-Methylcyclohexyl)-7-amino-1,8-naphthyridin-4(1H)-on-3-carboxamide 17.   
 Yield: 83%; mp 198-200 °C; 1H NMR: δ 10.45, 10.18 (2d, 1H, NH), 8.33, (s, 1H, H2), 8.13 
(d, 1H, H5), 7.12 (s, 2H, NH2), 6.55 (d, 1H, H6), 3.80 (m, 1H, CH), 1.86-0.85 (m, 12H, 
cyclohexyl + CH3). Anal. C16H20N4O2  C, H, N. 
 
7-Amino-N-cyclohexyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 18. 
Yield 79%; mp 275–278 °C (ethyl acetate). 1H NMR: DMSO δ 11.80 (brs, 1H, OH), 10.14 (d, 
1H, NH), 8.33 (s, 1H, H2), 8.10 (d, 1H, H5), 7.10 (s, 2H, NH2), 6.55 (d, 1H, H6), 3.90 (brs, 1H, 
CH), 1.84–1.29 (m, 10H, cyclohexyl). Anal. C15H18N4O2 C, H, N.  
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Experimental part scheme 3 
 
 
N-Cyclohexyl-7-fluoro-1,8-naphthyridin-4(1H)-on-3-carboxamide 26. 
Sodium nitrite (2.30 mmol) was added portionwise to a cooled solution (-5 °C) of 7-amino-
1,8-naphthyridin-3-carboxamide 1 (1.05 mmol) in 8 mL of  acqueous 50 % thetrafluoroboric 
acid. The mixture was stirred for 1h 30 min at r.t. and after cooling, was poured over crushed 
ice. The pH was adjusted to 9-10 with aqueous concentrated ammonium hydroxide. The solid 
obtained was collected by filtration, washed with water, and purified by flash chromatography 
(ethyl acetate).  
Yield: 46%; mp >300°C MS m/z 289; 1H NMR: DMSO δ 9.79 (d, 1H, NH), 8.75 (d, 1H, H5), 
8.65 (s, 1H, H2), 7.31 (dd, 1H, H6), 3.82 (br, 1H, CH), 1.86-1.22 (m, 10H, cyclohexyl). Anal. 
C15H16FN3O2 C, H, N. 
 
 
 
General procedure to the synthesis of  N-(4-Methylcyclohexyl) and N-cyclohexyl-7-
chloro-1,8-naphthyridin-4(1H)-on-3-carboxamide 19, 20. 
Sodium nitrite (0.34 g, 5.0 mmol) was added portion wise to a cooled solution (-5 °C) of 7-
amino-1,8-naphthyridine- 3-carboxamide 17 and 18 ( 1.0 mmol) in 54.5 mL of concentrated 
hydrochloric acid. The mixture was stirred for 3 h at 40 °C and, after cooling, was poured over 
crushed ice. The pH was adjusted to 4-5 with aqueous concentrated ammonium hydroxide. 
The solid obtained was collected by filtration, washed with water, and purified by flash 
chromatography (ethyl acetate/hexane, 1:1) to obtain  19 and 20. 
 
7-chloro -N-(4-Methylcyclohexyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide 19. 
Yield   31%; mp 271-273 °C (crystallized from ethyl acetate); 1H NMR: δ 10.00, 9.63 (2d, 
1H, NH), 8.64 (m, 2H, H2 + H5), 7.62 (d, 1H, H6), 3.80 (m, 1H, CH), 1.97-1.00 (m, 9H, 
cyclohexyl), 0.89, 0.92 (2d, 3H, CH3). Anal. C16H18ClN3O2  C, H, N. 
 
7-Chloro-N-cyclohexyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 20. 
Yield 52%; mp 266–268 °C. 1H NMR: DMSO δ 9.80 (d, 1H, NH), 8.65 (s, 1H, H2), 8.59 (d, 
1H, H5), 7.60 (d, 1H, H6), 3.85 (m, 1H, CH), 1.95–1.31 (m, 10H, cyclohexyl). Anal. 
C15H16ClN3O2 C, H, N.  
 
General Procedure for the Synthesis of N1-Substituted 1,8-Naphthyridine Derivatives   
27 and 21-25. 
An amount of 1,2 mmol of NaH was added to a solution of 1 mmol of 7-fluoro 26 or 7-chloro 
derivatives 19, 20 in 10 mL of dry N,N-dimethylformamide. After 1 h, the appropriate 
chloride (1 mmol) was added and the mixture was stirred for 24 h at 50 ° C for compound 21-
24 and  27 or  at  room temperature for 24 h for 25. The reaction mixture, after cooling in the 
was treated with water, and the precipitate formed was collected by filtration. 
 
N-Cyclohexyl-7-fluoro-1-(2-morpholin-4-yl-ethyl)-1,8-naphthyridin-4(1H)-on-3-
carboxamide 27.  
Yield: 71%; mp 171-173°C (crystallized from ethyl acetate), MS m/z 402; 1H NMR: DMSO δ 
10.14 (d, 1H, NH), 8.66 (s, 1H, H2), 8.23 (d, 1H, H5), 6.88 (d, 1H, H6), 4.50 (t, 2H, NCH2), 
3.85 (br, 1H, CH), 3.52 (s, 4H, morpholine),  2.68 (t, 2H, CH2N), 2.44 (s, 4H, morpholine), 
1.85-1.22 (m, 10H, cyclohexyl). Anal.C21H27FN4O3 C, H, N. 
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7-Chloro-N-cyclohexyl-1-(2-morpholin-4-ylethyl)-1,8-naphthyridin-4(1H)-on-3 
carboxamide  21.                                                                                                                         
Yield 70%; mp 188–190 °C. 1H NMR: DMSO δ 9.80 (d, 1H, NH), 8.96 (s, 1H, H2), 8.66 (d, 
1H, H5), 7.66 (d, 1H, H6), 4.62 (t, 2H, CH2N), 3.87 (m, 1H, CH), 3.47 (m, 4H, morpholine), 
2.66 (t, 2H, CH2N), 2.46 (m, 4H, morpholine), 1.88–1.23 (m, 10H, cyclohexyl). Anal. 
C21H27N4O3Cl  C, H, N. 
 
N-Cyclohexyl-1-benzyl-7-chloro-1,8-naphthyridin-4(1H)-on-3-carboxamide 22.  
Yield 70%; mp 258-260 °C (crystallized from hexane); MS m/z 395 (M+); 1H NMR: δ 9.72 
(d, 1H, NH), 9.12 (s, 1H, H2), 8.66 (d, 1H, H5), 7.67 (d, 1H, H6), 7.32 (m, 5H, Ar), 5.73 (s, 
2H, CH2), 3.85 (m, 1H, CH), 1.85-1.32 (m, 10H, cyclohexyl). Anal. C22H22ClN3O2 C, H, N. 
 
N-Cyclohexyl-7-chloro-1-(p-fluorbenzyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide 23. 
Purified by flash chromatography (ethyl acetate/hexane, 5:6), yield 25%; mp 198-200 °C 
(crystallized from cyclohexane); MS m/z 413 (M+); 1H NMR: δ 9.72 (d, 1H, NH), 9.14 (s, 1H, 
H2), 8.65 (d, 1H, H5), 7.68 (d, 1H, H6), 7.44 (m, 2H, Ar), 7.18 (m, 2H, Ar), 5.71 (s, 2H, CH2), 
3.89 (m, 1H, CH), 1.90-1.17 (m, 10H, cyclohexyl). Anal. C22H21ClFN3O2 C, H, N. 
 
N-Cyclohexyl-7-chloro-1-(o-fluorbenzyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide 24. 
Yield 0.300 g, 73%; mp 198-200°C (crystallized from cyclohexane); MS m/z 413 (M+); 1H 
NMR: δ 9.72 (d, 1H, NH), 9.11 (s, 1H, H2), 8.65 (d, 1H, H5), 7.67 (d, 1H, H6), 7.41-7.12 (m, 
4H, Ar), 5.76 (s, 2H, CH2), 3.85 (m, 1H, CH), 1.98-1.32 (m, 10H, cyclohexyl). Anal. 
C22H21ClFN3O2 C, H, N. 
 
N-(4′-Methylcyclohexyl)-7-chloro-1-(2-morpholin-4-yl-ethyl)-1,8-naphthyridin-4(1H)-on-
3-carboxamide 25.  
Purified by flash chromatography (ethyl acetate/hexane, 1: 1), yield 30%; mp 191-193 °C 
(crystallized from cyclohexane); MS m/z 432 (M+); 1H NMR: δ 10.20, 10.00 (2d, 1H, NH), 
8.65, 8,61 (2s, 1H, H2), 8.20, 8,18 (2d, 1H, H5), 6.87 (d, 1H, H6), 4.51 (m, 2H, CH2), 4.00 (m, 
1H, CH), 3.51 (m, 4H, morpholine), 2.67 (m, 2H, CH2), 2.44 (m, 4H, morpholine), 1.89-0.76 
(m, 12H, cyclohexyl + CH3). Anal. C22H29ClN4O3 C, H, N. 
 
N-Cyclohexyl-7-methoxy1-(2-morpholin-4-yl-ethyl)-1,8-naphthyridin-4(1H)-on-3-
carboxamide 28.  
A solution of sodium methylate 4.17 mmol, obtained by  4.17 mmol of sodium in 8 mL of 
methanol, was added to 0.18 mmol of 7-chloronaphtyridine  22 and heated for 5 h 30 min at 
80°C. The solvent was evaporated in vacuo and the solid obtained was treated with water and 
collected by filtration, and purified by flash chromatography ( AcOEt/Exane, 10:9) 
Yield: 56%; mp 212-215 °C, MS m/z 391; 1H NMR: DMSO δ  9.97 (d, 1H, NH), 9.04 (s, 1H, 
H2), 8.46 (d, 1H, H5), 7.33 (m, 5H, Ar), 6.97 (d, 1H, H6), 5.74 (s, 1H, CH2), 3.94 (s, 3H, 
OCH3), 3.90 (m, 1H, CH), 1.86-1.23 (m, 10H, cyclohexyl). Anal C23H25N3O3, C, H, N.                   
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Experimental part scheme 4 
 
 
N-Cyclohexyl-7-(N,N-dimethylamine)-1,8-naphthyridin-4(1H)-on-3-carboxamide 29. 
A mixture of 1 mmol of N-Cyclohexyl-7-cloro-1,8-naphthyridin-4(1H)-on-3-carboxylic acid 
ethyl ester 20 and 10 mmol of the dimethylamine was heated in sealed tube at 120°C for 24 h. 
After cooling, the reaction was treated with water to give a solid residue which was collected 
by filtration and purified by crystallization. Yield: 57,18%; mp 190-192°C (crystallized from 
ethyl acetate ), MS m/z 314; 1H NMR: DMSO δ 10.12 (d, 1H, NH), 8.36 (s, 1H, H2), 8.18 (d, 
1H, H5), 6.86 (d, 1H, H6), 3.80 (br, 1H, CH), 3.16 (s, 6H, 2CH3), 1.90-1.22 (m, 10H, 
cyclohexyl). Anal. C17H22N4O2 C, H, N. 
 
N-Cyclohexyl-7-(N,N-dimethylamine)-1-(2-morpholin-4-yl-ethyl)-1,8-naphthyridin-
4(1H)-on-3-carboxamide 30. 
An amount of 1,2 mmol of NaH was added to a solution of 1 mmol of  N,N-dimethyl-1,8-
naphthyridine-3-carboxamide derivative 29 in 10 mL of dry N,N-dimethylformamide. After 1 
h, the appropriate chloride (1 mmol) was added and the mixture was stirred at 50° C for 48h. 
The reaction mixture, after cooling was treated with water, and the precipitate formed was 
collected by filtration. 
Yield: 42,10%; mp 95-97°C (crystallized from ethyl acetate), MS m/z 427; 1H NMR: DMSO 
δ 10.11 (d, 1H, NH), 8.66 (d, 1H, H2), 8.23 (d, 1H, H5), 6.87 (d, 1H, H6), 4.50 (t, 2H, NCH2), 
3.80 (br, 1H, CH), 3.51 (s, 4H, morpholine), 3.17 (s, 6H, 2CH3), 2.67 (t, 2H, CH2N), 2.44 (s, 
4H, morpholine), 1.85-1.23(m, 10H, cyclohexyl). Anal  C23H33N5O3 C, H, N. 
 
N-Cyclohexyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 31. 
A solution of 7-chloronaphthyridine 2078 (0.40 g, 1.31 mmol) in methanol (20 mL) was 
submitted to hydrogenation in the presence  of 10% Pd/C (0.04 g) at room pressure and 
temperature for 3 h. 
The catalyst was filtered off, and the solvent was evaporated to dryness under reduced 
pressure to give a residual solid, which was purified by flash chromatography (ethyl acetate) 
and crystallized from hexane to give 31. 
Yield: 31%: mp 215-218 °C; 1H NMR: δ  9.85 (d, 1H, NH), 8.84 (dd, 1H, H7), 8.68 (s, 1H, 
H2), 8.65 (dd, 1H, H5), 7.55 (m, 1H, H6), 3.85 (m, 1H, CH), 1.86-1.22 (m, 10H, cyclohexyl). 
Anal. C15H17N3O2 C, H, N. 
 
General Procedure for the Synthesis of N1-Substituted 1,8-Naphthyridine Derivatives   
32-34. 
An amount of 1,2 mmol of NaH was added to a solution of 1 mmol of N-Cyclohexyl-1,8-
naphthyridin-4(1H)-on-3-carboxamide 31 in 10 mL of dry N,N-dimethylformamide. After 1 h, 
the appropriate chloride (1 mmol) was added and the mixture was stirred for 24 h at  room 
temperature for compounds 32 and 33 or at 50°C for 48 h for compound 34. The reaction 
mixture, after cooling in the was treated with water, and the precipitate formed was collected 
by filtration. 
 
N-Cyclohexyl-1-(p-fluorbenzyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide 32.  
Yield 0.185 g, 49%; mp 193-195 °C (crystallized from hexane); MS m/z 379 (M+); 1H NMR: 
δ  9.80 (d, 1H, NH), 9.15 (s, 1H, H2), 8.90 (dd, 1H, H7), 8.67 (dd, 1H, H5), 7.62 (m, 1H, H6), 
7.37 (m, 2H, Ar), 7.15 (m, 2H, Ar), 5.81 (s, 2H, CH2), 3.85 (m, 1H, CH), 1.86-1.23 (m, 10H, 
cyclohexyl). Anal. C22H22FN3O2 C, H, N. 
 
N-Cyclohexyl-1-benzyl-1,8-naphthyridin-4(1H)-on-3-carboxamide 33.  
 77
Yield 0.200 g, 55%; mp 181-183 °C (crystallized from hexane); MS m/z 361 (M+); 1H NMR: 
δ  9.95 (d, 1H, NH), 9.12 (s, 1H, H2), 8.90 (dd, 1H, H7), 8.70 (dd, 1H, H5), 7.70 (m, 1H, H6), 
7.29 (m, 5H, Ar), 5.84 (s, 2H, CH2), 3.85 (m, 1H, CH), 1.86-1.30 (m, 10H, cyclohexyl). Anal. 
C22H23N3O2 C, H, N. 
 
N-Cyclohexyl-1-(2-morpholin-4-yl-ethyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide 34. 
Yield 0.155 g, 40%; mp 142-144 °C (crystallized from hexane); MS m/z 384 (M+); 1H NMR: 
δ  9.84 (d, 1H, NH), 8.98 (s, 1H, H2), 8.90 (dd, 1H, H7), 8.68 (dd, 1H, H5), 7.60 (m, 1H, H6), 
4.66 (t, 2H, CH2), 3.86 (m, 1H, CH), 3.49 (m, 4H, morpholine), 2.70 (m, 2H, CH2), 2.44 (m, 
4H, morpholine),1.85-0.82 (m, 10H, cyclohexyl). Anal. C21H28N4O3  C, H, N. 
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Experimental part scheme 5 
 
N-Cyclohexyl-7-hydroxy-1,8-naphthyridin-4(1H)-on-3-carboxamide 35.  
Sodium nitrite (0.55 g, 8.0 mmol) was added portionwise to a cooled solution (-10 °C) of 7-
amino-1,8- naphthyridine-3-carboxamide 1878 (0.44 g, 1.6 mmol) in 7 mL of concentrated 
sulfuric acid. After standing for 4 h at room temperature, the mixture was poured over crushed 
ice and the pH was adjusted to 8 with aqueous concentrated ammonium hydroxide. The solid 
obtained was collected by filtration, washed with water, and purified by crystallization from 
toluene to obtain 35. 
 yield 94%: mp 303-305 °C; 1H NMR: δ  10.49 (d, 1H, NH), 8.45 (s, 1H, H2), 8.10 (d, 1H, 
H5), 6.25 (d, 1H, H6), 3.78 (m, 1H, CH), 1.82-1.26 (m, 10H, cyclohexyl). Anal. C15H17N3O3  
C, H, N. 
 
N-Cyclohexyl-1-(o-fluorobenzyl)-7-(o-fluorobenzyloxy)-1,8-naphthyridin-4(1H)-on-3-
carboxamide 36.  
NaH (0.05 g, 1.08 mmol, 50% in mineral oil) was added to a solution of 7-hydroxy-1,8 
naphthyridine 35 (0.25 g, 0.87 mmol) in 6 mL of dry DMF. After 1 h, 2-fluorobenzyl chloride 
(0.125 g, 0.87 mmol) was added and the mixture was stirred for 3 days at 80 °C. After the 
mixture was cooled, water was added and the solid obtained was collected by filtration, 
purified by flash chromatography (ethyl acetate/hexane, 1:1), and crystallized from 
cyclohexane to give 36. 
 yield 30%: mp 198-200 °C; MS m/z 503 (M+); 1H NMR: δ  9.94 (d, 1H, NH), 9.03 (s, 1H, 
H2), 8.52 (d, 1H, H5), 7.47-7.10 (m, 8H, 2Ar), 7.03 (d, 1H, H6), 5.80 (s, 2H, CH2), 5.43 (s, 2H, 
CH2), 3.85 (m, 1H, CH), 1.32 (m, 10H, cyclohexyl). Anal. C29H27F2N3O3  C, H, N. 
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Experimental part scheme 6 
 
General procedure to the synthesis of ethyl-α-carboxy-β-subsituted-anilinacrilate 37-39. 
A mixture of 1.22 mmol of the suitable aniline and 1.22 mmol of EMME was heated at 110°C 
for 2 h for the compound 37, at 100°C for 3h 30 min for the compound 38 or at 130°C for 5 h 
for the compound 39. After cooling the compound 37 was purified by flash chromatography 
(exane/ ethyl acetate 13:3). In the case of comound 39 the oil obtained was used without 
purification. 
 
Ethyl- α-carboxy-β-anilinacrilate 37. 
Yield: 97%; mp: 264-269°C; 1H NMR: δ 11.00 (d, 1H, NH), 8.55 (d, 1H, CH), 7.38 (m, 2H, 
Ar), 7.17 (m, 3H, Ar), 4.30 (q, 4H, 2CH2), 1.35 (t, 6H, 2CH3). Anal. C14H17NO4 C, H, N.  
 
Ethyl- α-carboxy-β-m-chloro-anilinacrilate 38.  
Yield: 98%; mp: 275-278°C; 1H NMR: δ 11.10 (d, 1H, NH), 8.52 (d, 1H, CH), 7.40 (s, 1H, 
Ar), 7.10 (m, 3H, Ar), 4.36 (q, 4H, 2CH2), 1.30 (t, 6H, 2CH3).  
 
Ethyl- α-carboxy-β-m-methoxy-anilinacrilate 39. 
Yield: 97%; mp: 264-269°C; 1H NMR: δ 11.00 (d, 1H, NH), 8.50 (d, 1H, Ar),  7.60 (s, 1H, 
CH), 7.28 (m, 1H, Ar), 6.68 (m, 3H, Ar), 4.30-4.21 (q, 4H, 2CH2), 3.83 (s, 3H, OCH3) 1.33 (t, 
6H, 2CH3). Anal. C15H19NO5 C, H, N.  
 
General procedure to the synthesis of 7-subsituted- quinoline-3-carboxylic acid ethyl 
ester 40-42 
A mixture of 0.018 mol of  suitable ethyl-α-carboxy-β-subsituted-anilinacrilate and ml 25 of 
Dowtherm A was heated at reflux for 1 h for the compounds 40, 41 or for 30 min for the 
compound 42. After cooling the solid obtained was washed with petroleum ether and collected 
by filtration. 
 
Ethyl-4-oxo-quinolin-3-carboxylate 40. 
Yield: 66%; mp: 270-271° C; 1H NMR: δ 12.20 (br, 1H, NH), 8.54 (s, 1H, H2), 8.15 (d, 1H, 
H5), 7.02 (m, 3H, Ar), 4.22  (q, 2H, CH2), 1.27 (t, 3H, CH3). 
 
Ethyl-7-chloro-4-oxo-quinolin-3-carboxylate 41.   
Yield: 80%; mp: 240-243° C; 1H NMR: δ 12.10 (br, 1H, NH), 8.50 (s, 1H, H2), 8.10 (d, 1H, 
H5), 7.08 (m, 2H, Ar), 4.20  (q, 2H, CH2), 1.22 (t, 3H, CH3) 
 
Ethyl-7-methoxy-4-oxo-quinolin-3-carboxylate 42. 
Yield: 70%; mp: 233-236° C; 1H NMR: δ 12.00 (br, 1H, NH), 8.48 (s, 1H, H2), 8.05 (d, 1H, 
H5), 7.00 (m, 2H, Ar), 4.19  (q, 2H, CH2), 3.60 (s, 3H, OCH3), 1.26 (t, 3H, CH3). Anal. 
C13H13NO4 C, H, N. 
 
 
 General procedure to the synthesis of N-substituted-quinolin-4(1H)-on-3-carboxamide 
43-46. 
A mixture of 1 mmol of suitable  quinoline-3-carboxylic acid ethyl ester 4083-42 and 10 mmol 
of opportune amine in a sealed tube was heated at 120 °C for 24 h. After cooling, the reaction 
mixture was treated with ethyl ether to give a solid residue, which was collected by filtration 
and purified by crystallization from ethyl acetate. 
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N-Cyclohexyl-quinolin-4(1H)-on-3-carboxamide 43 
 Yield 0.230 g, 88%; mp 112-114 °C; 1H NMR: δ 10.10 (d, 1H, NH), 8.72 (s, 1H, H2), 8.24 (d, 
1H, Ar), 7.70 (m, 2H, Ar), 7.47 (m, 1H, Ar), 3.82 (m, 1H, CH), 1.86-1.31 (m, 10H, 
cyclohexyl). Anal. C16H18N2O2  C, H, N. 
 
N-Cyclohexyl-7-chloroquinolin-4(1H)-on-3-carboxamide 44.  
 yield 0.275 g, 90%; mp 132-135 °C; 1H NMR: δ 10.18 (d, 1H, NH), 8.72 (s, 1H, H2), 8.21 (d, 
1H, Ar), 7.69 (s, 1H, Ar), 7.40 (d, 1H, Ar), 3.81 (m, 1H, CH), 1.85-1.08 (m, 10H, cyclohexyl). 
Anal. (C16H17ClN2O2 ) C, H, N. 
 
N-Cylohexyl-7-methoxyquinolin-4(1H)-on-3-carboxamide 45. 
Yield: 52.70%; mp 211-214°C; (crystallization from ethyl acetate) MS m/z 300; 1H NMR: 
DMSO δ 10.13 (d, 1H, NH), 8.64 (s, 1H, H2), 8.13 (d, 1H, H5), 7.09-7.03 (m, 2H, H6+H8), 
3.87-3.75 (m, 4H, OCH3+CH), 1.86-1.08 (m, 10H, cyclohexyl). Anal. C17H20N2O3   C,H,N. 
 
N-Cycloheptyl-quinolin-4(1H)-on-3-carboxamide 46. 
 Yield: 77.55%; MS m/z  284; 1H NMR: CDCl3 δ 10.55 (d, 1H, NH), 8.45 (d, 1H, Ar), 7.71 
(m, 2H, Ar), 7.49 (m,1H, Ar), 4.32 (m, 1H, NCH), 2.10-1.62 (m, 12H, cycloheptyl). Anal 
C17H20N2O2 C,H,N. 
 
General Procedure for the Synthesis of N1-Substitutedquinoline Derivatives 47-54. 
 NaH (4.36 mmol, 50% in mineral oil) was added to a solution of N-substituted quinoline-3-
carboxamide (0.92 mmol) in 9.2 mL of dry DMF at room temperature, in the case of 
derivatives 44 or 45 the solution was heated at 50°C. After 1 h, 4-(2-chloroethyl)-morpholine 
hydrochloride or benzyl chloride (0.92 mmol) was added, and the mixture was stirred for 24 h, 
at 50 °C for compounds 47, 49 and 50-54  or at 80 °C for compound 48. After the mixture was 
cooled (3-5 °C), the addition of water caused the precipitation of the title compounds, which 
were purified by crystallization in the cases of 47-50, and 52-54, or by flash chromatography  
for 51. 
 
N-Cyclohexyl-1-(2-morpholin-4-ylethyl)-quinolin-4(1H)-on-3-carboxamide 47.  
Yield 0.180 g, 50%; mp 169-170 °C (crystallized from ethyl acetate); MS m/z 383 (M+); 1H 
NMR: δ 10.04 (d, 1H, NH), 8.80 (s, 1H, H2), 8.34 (d, 1H, Ar), 7.90 (m, 2H, Ar), 7.52 (m, 1H, 
Ar), 4.58 (m, 2H, CH2), 3.90 (m, 1H, CH), 3.49 (m, 4H, morpholine), 2.65 (m, 2H, CH2), 2.42 
(m, 4H, morpholine), 1.88-1.22 (m, 10H, cyclohexyl). Anal. (C22H29N3O3 ) C, H, N. 
 
N-Cyclohexyl-1-benzylquinolin-4(1H)-on-3-carboxamide 48. 
Yield 62%; mp 239-240 °C (crystallized from hexane); MS m/z 360 (M+); 1H NMR: δ 10.05 
(d, 1H, NH), 8.97 (s, 1H, H2), 8.54 (d, 1H, Ar), 7.61-7.15 (m, 8H, Ar), 5.48 (s, 2H, CH2), 3.98 
(m, 1H, CH), 2.02-1.44 (m, 10H, cyclohexyl). Anal. (C23H24N2O2 ) C, H, N. 
 
N-Cyclohexyl-7-chloro-1-(2-morpholin-4-ylethyl)-quinolin-4(1H)-on-3-carboxamide 49. 
Yield 52%; mp 229-231 °C (crystallized from ethyl acetate); MS m/z 417 (M+). 1H NMR: δ 
10.00 (d, 1H, NH), 8.80 (s, 1H, H2), 8.35 (d, 1H, Ar), 8.05 (m, 1H, Ar), 7.60 (m, 1H, Ar), 4.50 
(s, 2H, CH2), 3.80 (m, 1H, CH), 3.47 (m, 4H, morpholine), 2.45 (m, 6H, CH2 + morpholine), 
1.40-1.05 (m, 10H, cyclohexyl). Anal. (C22H28ClN3O3 ) C, H, N. 
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N-Cyclohexyl-1-benzyl-7-methoxyquinolin-4(1H)-on-3-carboxamide 50. 
Yield: 66.66%; mp 126-129°C (crystallized from exane), MS m/z 390 ; 1H NMR: DMSO δ 
10.22 (d, 1H, NH), 8.99 (d, 1H, H2), 8.33 (d, 1H, H5), 7.36-7.08 (m, 7H, H6+H8+Ar), 5.75 (s, 
1H, CH), 3.78 (s, 3H, OCH3), 1.86-1.22 (m, 10H, cyclohexyl). Anal. C24H26N2O2 C, H, N. 
 
N-Cyclohexyl-7-methoxy-1-(2-morpholin-4-yl-ethyl)-quinolin-4(1H)-on-3-carboxamide 
51. 
Yield: 22 %; mp 145-148 °C,( flash chromatography AcOEt/ MeOH/ Exane,10:1.5:3) MS m/z     
413 ; 1H NMR: DMSO δ 10.10 (d, 1H, NH), 8.71 (s, 1H, H2), 8.23 (d, 1H, H5),  7.21(s, 1H, 
H8) 7.18 (d, 1H, H6), 4.55 (t, 2H, NCH2), 3.94 (s, 3H, OCH3), 3.80 (br, 1H, CH), 3.52 (m, 4H, 
morpholine), 2.67 (t, 2H, CH2N), 2.48 (m, 4H, morpholine), 1.85-1.25 (m, 10H, cyclohexyl). 
Anal. C23H31N3O4 C, H, N.  
N-Cycloheptyl-1-benzylquinolin-4(1H)-on-3-carboxamide 52. 
Yield: 50.10%; mp 203-206°C (crystallized from ethyl acetate), MS m/z 374 ; 1H NMR: 
CDCl3 δ 10.10 (d, 1H, NH), 8.95 (s, 1H, H2), 8.54 (d, 1H, Ar), 7.65-7.15 (m, 8H, Ar), 5.48 (s, 
2H, NCH2), 4.24 (br, 1H, CH), 2.02-0.90 (m, 12H, cycloheptyl). Anal. C24H26N2O2 C, H, N. 
 
N-Cycloheptyl-1-(2-morpholin-4-yl-ethyl)-quinolin-4(1H)-on-3-carboxamide 53. 
Yield: 63.34%; mp 158-160 °C,(crystallization from ethyl acetate) MS m/z 397 ; 1H NMR: 
CDCl3 δ 10.03 (d, 1H, NH), 8.79 (s, 1H, H2), 8.53 (d, 1H, H5),  7.75 (d, 1H, H8) 7.52 (m, 2H, 
H6+H7), 4.36 (s, 2H, NCH2), 3.84 (m, 1H, CH), 3.70 (m, 4H, morpholine), 2.81 (s, 2H, 
CH2N), 2.52 (m, 4H, morpholine)  2.02-0.84 (m, 12H, cycloheptyl). Anal. C23H31N3O3 C, H, 
N. 
 
N-Cyclohexyl-1-benzyl-7-chloroquinolin-4(1H)-on-3-carboxamide 54.  
Yield 62%; mp >300°C (crystallized from hexane); MS m/z 360 (M+); 1H NMR: δ 8.48 (s, 
1H, H2), 7.93 (d, 1H, Ar), 7.35-7.28 (m, 7H, Ar), 4.54 (s, 2H, CH2), 3.48 (m, 1H, CH), 2.08-
0.98 (m, 10H, cyclohexyl). Anal. C23H23N2O2 Cl C, H, N. 
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Experimental part scheme 7 
 
 
General Procedure for the Preparation of N1-Substituted 4-Hydroxy-7-methyl-1,2,3,4-
tetrahydro-1,8-naphthyridin-3-carboxamides 58-60. 
 NaBH4 (0.30 g, 8 mmol) was added to a solution of the appropiate 7-methyl-1,8-
naphthyridin-4(1H)-on-3-carboxamide derivatives78 (0.38 mmol) in absolute ethanol (7.5 mL), 
and the mixture was stirred at room temperature for 12h. The organic solvent was evaporated 
from the reaction mixture under reduced pressure to obtain a residue, which was treated with 
H2O. In the cases of 58 and 60, the solid precipitate obtained was collected by filtration and 
purified by crystallization from hexane, whereas for 59 the mixture was extracted with 
chloroform, the organic solution was dried (MgSO4) and evaporated to dryness under reduced 
pressure, and the crude solid was purified by crystallization from cyclohexane. 
 
N-Cyclohexyl-1-(o-fluorbenzyl)-4-hydroxy-7-methyl-1,2,3,4-tetrahydro-1,8-
naphthyridin-3-carboxamide 58.  
Yield 87%; MS m/z 397 (M+); 1H NMR: δ 7.82 (m, 1H, NH), 7.40 (d, 1H, H5), 7.30-7.08 (m, 
4H, Ar), 6.44 (d, 1H, H6), 5.63 (d, 1H, OH), 4.95-4.69 (m, 3H, CH2 + H4), 3.56 (m, 1H, CH), 
3.30 (m, 2H, 2H2), 2.23 (s, 3H, CH3), 1.68-1.11 (m, 11H, cyclohexyl+H3). Anal. C23H28FN3O2  
C, H, N. 
 
4-Hydroxy-N-(4-methylcyclohexyl)-1-(2-morpholin-4-ylethyl)-7-methyl-1,2,3,4-
tetrahydro-1,8-naphthyridin-3-carboxamide 59. 
Yield 61%; MS m/z 416 (M+).1H NMR: δ 7.81 (m, 1H, NH), 7.34 (d, 1H, H5), 6.35 (d, 1H, 
H6), 5.55 (m, 1H, OH), 4.61 (m, 1H, H4), 3.78 (m, 1H, CH), 3.57-3.33 (m, 8H, morpholine + 
NCH2 + 2H2), 2.45 (m, 6H, morpholine + CH2), 2.22 (s, 3H, CH3), 1.70-1.05 (m, 13H, 
cyclohexyl + CH3 + H3). Anal. C23H36N4O3 C, H, N. 
 
N-Cyclohexyl-1-benzyl-4-hydroxy-7-methyl-1,2,3,4-tetrahydro-1,8-naphthyridin-3-
carboxamide 60.  
Yield 52%; MS m/z 379 (M+); 1H NMR: δ 7.48 (d, 1H, H5), 7.31 (m, 5H, Ar), 6.48 (m, 1H, 
H6), 6.00 (d, 1H, OH), 4.92 (m, 3H, CH2 + H4), 3.74 (m, 1H, CH), 3.40 (m, 2H, 2H2), 2.57 
(m, 1H, H3), 2.38 (s, 3H, CH3), 1.84-0.83 (m, 10H, cyclohexyl). Anal. C23H29N3O2 C, H, N
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Experimental part scheme 8 
 
General procedure for the synthesis of 4-chloro 7-substituted-quinolin-3-carboxylate 61, 
62. 
A mixture of  1 mmol of  suitable 4-hydroxyquinoline-3-carboxylic acid ethyl ester 39, 40 and 
2 mmol of phosphoryl trichloride was stirred at 120°C for 15 min. After cooling the reaction 
mixture was poured over crushed ice and the pH was adjusted to 8-9 with concentrated 
ammonium hydroxide. The solid obtained was collected by filtration. 
 
4-chloroquinoline-3-carboxylate 61. 
Yield: 72.90%; mp: 43-44°C; 1H NMR: DMSO δ 11.03 (d, 1H, NH), 9.00 (s, 1H, H2), 8.57 (s, 
1H, Ar),  8.11 (d,1H, Ar), 7.72-7.51 (m, 2H, Ar), 4.21 (q, 2H, CH2), 1.36 (t, 3H, CH3). Anal: 
C12H11NO2Cl C, H, N,. 
 
4,7-dichloroquinoline-3-carboxylate 62. 
Yield: 87.44%; 1H NMR: DMSO δ 10.23 (d, 1H, NH), 9.18 (s,1H, H2), 8.38 (d,1H, H5), 8.23 
(s, 1H, H8), 7.89 (d, 1H, H6), 4.23 (q, 2H, CH2), 1.38 (t, 3H, CH3). Anal: C12H10NO2Cl2 C, H, 
N,. 
 
General Procedure for the Synthesis of 2-Substituted-2,5-dihydroxy-3H-pyrazol-[4,3-
c]quinoline 63-65. 
A mixture of 1 mmol of   4-cloroquinoline-3-carboxylic acid ethyl ester 61 or 6285, 1 mmol of 
cyclohexyhydrazine hydrochloride or phenylhydarzine and 3 mmol of triethylamine in 10 ml 
of p-xilene was stirred at 150 °C for 12h 30 min. The precipitate formed was collected by 
filtration,  treated with water and purified by cristallization. 
 
2-Cyclohexyl-2,5-dyhydroxy-3H-pyrazol-[4,3-c]quinoline 63.  
Yield:76.42%, mp 198-202°C (crystallized from exane) MS m/z 276; 1H NMR: CDCl3 δ 9.35 
(d, 1H, NH), 8.77 (s, 1H, H2), 8.35 (d, 1H, H5), 7.88 (d, 1H, H8), 7.34 (m, 2H, H6+H7), 4.66 
(br, 1H, CH), 2.07-1.26 (m, 10, cyclohexyl). Anal. C16H17N3O  C, H, N.   
2-phenyl-2,5-dyhydroxy-3H-pyrazol-[4,3-c]quinoline 64. 
Yield: 75.35%; mp: >300°C; 1H NMR: DMSO δ 9.20 (d, 1H, NH), 8.73 (s, 1H, H2), 8.21 (d, 
2H, Ar),  7.70-7.34 (m, 6H, Ar), 7.18 (m, 1H, H7). Anal. C16H11N3O  C, H, N.   
2-Cyclohexyl-7-chloro-2,5-dyhydroxy-3H-pyrazol-[4,3-c]quinoline 65.  
Yield:80.05%, mp > 300°C (crystallized from DMF) MS m/z 300; 1H NMR: CDCl3 δ 9.23 (d, 
1H, NH), 8.73 (s, 1H, H2), 8.27 (d, 1H, H5), 7.86 (d, 1H, H8), 7.46 (m, 1H, H6), 4.36 (br, 1H, 
CH), 2.05-1.26 (m, 10, cyclohexyl). Anal. C16H16N3OCl  C, H, N. 
 
General Procedure for the Synthesis of N1-Substituted 2,5-dihydroxy-3H-pyrazol-[4,3-
c]quinoline Derivatives 66-70. 
 An amount of 1,2 mmol of NaH  (50% in mineral oil) was added to a solution of 1 mmol of 
63 or 64 or of  7-chloroquinoline derivative 65 in 10 mL of dry N,N-dimethylformamide. 
After 1 h, the appropriate chloride (1 mmol) was added and the mixture was stirred for 24 h at  
room temperature for compound  66, 67 or at 50°C for compound 68, 69 or at 70°C for 70. 
The reaction mixture, after cooling  was treated with water, and the precipitate formed was 
collected by filtration. 
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5-Benzyl-2-cyclohexyl-2,5-dihydroxy-3H-pyrazol-[4,3-c]quinoline-3-one 66. 
Yield: 53,85%; mp 202-206°C (crystallized from exane), MS m/z 357; 1H NMR: DMSO δ 9.2 
(s, 1H, H2), 8.27 (d, 1H, H5), 7.91 (d, 1H, H8), 7.64-7.40 (m, 7H, Ar+H6+H7), 5.79 (s, 2H, 
CH2 ), 4.45 (br, 1H, CH), 1.98-1.09 (m, 10H, cyclohexyl). Anal. C23H23N3O  C, H, N. 
 
5-Benzyl-7-chloro-2-cyclohexyl-2,5-dihydroxy-3H-pyrazol-[4,3-c]quinoline-3-one 67. 
Yield: 59.03%; mp 185-188°C (crystallized from ethyl acetate), MS m/z 390; 1H NMR: 
CDCl3 δ 9.05 (s, 1H, H2), 8.37 (d, 1H, H5), 8.01 (d, 1H, H8), 7.53-7.40 (m, 6H, Ar+H6), 5.64 
(s, 2H, CH2 ), 4.45 (br, 1H, CH), 2.10-1.27 (m, 10H, cyclohexyl). Anal. C23H22N3OCl C, H, 
N. 
 
2-Cyclohexyl-2,5-dihydroxy-5-(2-morpholin-4-yl-ethyl)-3H-pyrazol-[4,3-c]quinoline-3-
one 68.  
Yield: 44.53%; mp 118-122°C (crystallized from ethyl acetate), MS m/z 380; 1H NMR: 
DMSO δ 9.25 (d, 1H, NH), 8.89 (s, 1H, H2), 8.41 (d, 1H, H5), 8.12 (d, 1H, H8), 7.82-7.72 (m, 
2H, H6+H7), 4.96 (br, 1H, CH), 4.51 (s, 2H, CH2 ), 3.37-3.33 (m, 4H, morpholine), 2.79 (t, 
2H, CH2 ), 2.56-2.50 (m, 4H, morpholine), 2.06-1.08 (m, 10H, cyclohexyl). Anal. C22H28N4O2 
C, H, N. 
 
2-phenyl-2,5-dihydroxy-5-(2-morpholin-4-yl-ethyl)-3H-pyrazol-[4,3-c]quinoline-3-one 
69. 
Yield: 31.64%; mp 233-237°C (crystallized from ethyl acetate), MS m/z 374; 1H NMR: 
DMSO δ 8.78 (s, 1H, H2), 8.21 (d, 2H, H5+ H8), 7.75-7.41 (m, 6H, Ar+H6), 7.17 (m, 1H, H7), 
4.58 (t, 2H, CH2), 3.52 (m, 4H, morpholine), 2.71 (t, 2H, CH2 ),2.50 (m, 4H, morpholine). 
Anal. C22H22N4O2 C, H, N. 
 
2-Cyclohexyl-7-chloro-2,5-dihydroxy-5-(2-morpholin-4-yl-ethyl)-3H-pyrazol-[4,3-
c]quinoline-3-one 70.  
Yield: 33.94%; mp > 300°C (crystallized from ethyl acetate), MS m/z  413; 1H NMR: CDCl3 
δ 8.35 (s, 1H, H2), 8.30 (d, 1H, H5), 7.56 (s, 1H, H8), 7.46 (d, 1H, H6), 4.40 (m, 1H, NCH), 
4.31 (t, 2H, NCH2), 3.73-3.69 (m, 4H, morpholine), 2.82 (t, 2H, CH2N), 2.54 (m, 4H, 
morpholine), 2.06-1.23 (m, 10H, cyclohexyl). Anal. C22H27N4O2Cl  C, H, N. 
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Experimental part scheme 9 
 
 
Dimethyl-N-[(6-acetylamino)-2-pyridin-yl]-aminofumarate 71. 
A mixture of 5.28 mmol of  2-acetylamino-6-aminopyridine and 5.28 mmol of with 
acetylendicarboxylic acid dimethyl ester  in 27 ml of methanol  was heayted at 80°C for 24h. 
The solution was concentrated and cooling in ice. The solid obtained was collected by 
filtration to give the dimethyl ester 71. 
Yield: 65%; mp: 125-130°C; IR: 1736.99 cm-1 (C=O). 
 
7-aminoacetyl-4-oxo-1,8-naphthyridin-2-carboxylic acid methyl ester 72. 
 A mixture of 5.1 mmol of Dimethyl-N-[(6-acetylamino)-2-pyridin-yl]-aminofumarate in 30 
ml of Dowtherm A was heated at reflux  for 30 min. After cooling the solid obtained was 
washed with petroleum ether and collected by filtration, to gave the 2-methylester 72 purified 
by flash-chromatography on silica gel eluiting with AcOEt/MeOH 10:1.   
Yield: 65%; mp: 125-130°C; 1H NMR: DMSO δ 11.81 (s, 1H, NH), 10.69 (s, 1H, OH), 7.99 
(d, 1H, H5), 6.51 (m, 2H, Ar), 3.91 (s, 3H, OCH3), 2.21 (s, 3H, CH3). Anal C12H11N3O4, C, H, 
N,. 
 
7-amino-N-cyclohexyl-1,8-naphthyridin-4(1H)-on-2-carboxamide 73. 
A mixture of 1,8-naphthyridine-2-carboxylic acid methyl ester  (1 mmol) and 10 mmol of 
cyclohexylamine amine was heated in a sealed tube at 120°C for 24h. After cooling, the 
reaction mixture was treated with ethyl ether to give a solid residue, which was collected by 
filtration and purified by crystallization from ethyl acetate. 
Yield 87 %; mp 185–188 °C. 1H NMR: DMSO δ  8.63 (d, 1H, NH), 7.90 (d, 1H, H5), 6.90 (br, 
2H, NH2), 6.53 (d, 1H, H3), 6.49 (d, 1H, H6), 3.73 (br, 1H, CH), 1.98–1.20 (m, 10H, 
cyclohexyl).  
 
 
7-amino-1-benzyl-N-cyclohexyl-1,8-naphthyridin-4(1H)-on-2-carboxamide 74. 
An amount of 1,2 mmol of NaH was added to a solution of 1 mmol of 7-amino-N-cyclohexyl-
1,8-naphthyridin-4(1H)-on-2-carboxamide in 10 mL of dry N,N-dimethylformamide. After 1 
h,  the benzyl chloride (1 mmol) was added and the mixture was stirred for 24 h at 50° C. The 
reaction mixture, after cooling was treated with water, and the precipitate formed was 
collected by filtration and purified by flash cromatogrphy.( ethyl acetate/ exane 1:1 ) 
Yield 40 %; mp 204-207 °C. 1H NMR: CDCl3 δ  8.33 (d, 1H, NH), 8.22 (d, 1H, H5), 7.72(s, 
1H, H3), 7.52-7.39 (m, 5H, Ar), 6.77 (d, 1H, H6), 5.34 (s, 2H, NCH2), 5.12 (br, 2H, NH2) 3.93 
(br, 1H, CH), 2.26–1.20 (m, 10H, cyclohexyl). Anal. C22H24N4O2, C, H, N. 
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Experimental part scheme 10 
 
 
ethyl-2-oxo-1,8-naphthyrydin-3-carboxylate 75. 
A solution of 1 g (8,19 mmol) of 2-aminopyridin-3-carboxaldehyde, 1,85 ml of ethyl malonate 
and few drops of piperidine was heated at 120°C for 20h. Afetr cooling the precipitate was 
treated with ethyl ether to give the compound 75 as a yellow solid, cristallized from ethyl 
acetate. 
Yield: 76%; mp 182-185°C; 1H NMR: δ 8.60 (dd, 1H, H7), 8.50 (s, 1H, H4), 8.26 (dd, 1H, H5), 
7.29 (dd, 1H, H6), 4.32-4.22 (q, 2H, CH2), 1.29 ( t, 3H, CH3). 
 
General procedure to the synthesis of N-substituted-1,8-naphthyridin-2(1H)-on-3-
carboxamide 76-81. 
A mixture of 1 mmol of ethyl ester and 10 mmol of the appropriate amine in a sealed tube was 
heated at 120°C for 24h. After cooling, the reaction mixture was treated with ethyl ether to 
give a solid residue which was collected by filtration and purified by crystallization from ethyl 
acetate (76 and 77) or from ethanol (78- 81).  
 
N-Cyclohexyl-1,8-naphthyridin-2(1H)-on-3-carboxamide 76. 
Yield  88%; mp 277-280 °C; 1H NMR: δ 9.70 (d, 1H, NH), 8.85 (s, 1H, Ar), 8.66 (dd, 1H, 
Ar), 8.42 (dd, 1H, Ar), 7.36 (dd, 1H, Ar), 3.85 (m, 1H, CH), 1.89-1.27 (m, 10H, cyclohexyl). 
Anal. C15H17N3O2  C, H, N.  
 
N-(4-methylcyclohexyl)-1,8-naphthyridin-2(1H)-on-3-carboxamide 77. 
 Yield  87%; mp 158-161 °C; 1H NMR: δ 10.0, 9.60 (2d, 1H, NH), 8.85 (s, 1H, Ar), 8.66 (dd, 
1H, Ar), 8.42 (dd, 1H, Ar), 7.36 (m, 1H, Ar), 4.16, 3.80 (2m, 1H, CH), 2.00-1.05 (m, 9H, 
4CH2+CH), 0.92, 0.89 (2d, 3H, CH3). Anal. C16H19N3O2  C, H, N.  
 
N-2(2-aminoethyl)pyridin-1,8-naphthyridin-2(1H)-on-3-carboxamide 78. 
Yield 82%; mp >300 °C; 1H NMR: δ 9.78 (t, 1H, NH), 8.85 (s, 1H, Ar), 8.65 (dd, 1H, Ar),   
8.41 (dd, 1H, Ar), 7.72 (dd, 1H, Ar). 7.39-7.24 (m, 4H, Ar), 3.74 (q, 2H, CH2), 3.01 (t, 2H, 
CH2 ). Anal. C16H14N4O2 C, H, N. 
 
N-(β-phenylethyl)-1,8-naphthyridin-2(1H)-on-3-carboxamide 79. 
 Yield 87%; mp 270-272°C; 1H NMR: δ 9.17 (t, 1H, NH), 8.86 (s, 1H, Ar), 8.65 (dd, 1H, Ar), 
8.40 (dd, 1H, Ar),  7.39-7.25 (m, 6H, Ar), 3.59 (m, 2H, CH2), 2.85 (t, 2H, CH2). Anal. 
C17H15N3O2 C, H, N.  
 
N-(4-fluoro-phenylethyl)-1,8-naphthyridin-2(1H)-on-3-carboxamide 80. 
Yield 84%; mp >300°C; 1H NMR: δ 9.68 (t, 1H, NH), 8.85 (s, 1H, Ar), 8.65 (d, 1H, Ar), 8.40 
(d, 1H, Ar),  7.39-7.28 (m, 3H, Ar), 7.17-7.07 (m, 2H, Ar), 3.58 (m, 2H, CH2), 2.85 (t, 2H, 
CH2 ). Anal. C17H14N3O2  F C, H, N.   
 
N-Cycloepthyl-1,8-naphthyridin-2(1H)-on-3-carboxamide 81. 
yield 71%; mp 200-204°C 1H NMR: δ 9.75 (t, 1H, NH), 8.84 (s, 1H, Ar), 8.65 (dd, 1H, Ar), 
8.40 (dd, 1H, Ar), 7.35 (dd, 1H, Ar). 4.10(brs, 1H, CH), 1.90-1.45 (m, 12H, cycloepthyl). 
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 General Procedure for the Synthesis of N1-Substituted1,8-naphthyridin-2(1H)-on-3-
carboxamide 82-93. 
NaH (0.10 g, 2.00 mmol, 50 % in mineral oil) was added to a solution of  suitable 1,8-
naphthyridine-2(1H)-on-3-carboxamide derivatives 76, 77 and 79-81 (0.81 mmol) in 6.4 mL 
of dry DMF. After 1h, the suitable chloride (0.81 mmol) was added and the mixture was 
stirred for 24 h at room temperature (82-84, and  85, 87-91) or at 50 °C (86 and 92) or at 70°C 
(93). After cooling,  water was added and the solid obtained was collected by filtration and 
was purified by crystallization from hexane (82, 84, 85 and 93) or from ethyl acetate (87 and 
88) or ethanol (89) or by flash chromatography [86, 92 (ethyl acetate: methanol, 10:0.5)].  
 
N-Cyclohexyl-1-benzyl-1,8-naphthyridin-2(1H)-on-3-carboxamide 82. 
Yield: 61%; mp 154-156 °C; 1H NMR: δ 9.58 (d, 1H, NH), 8.96 (s, 1H, Ar), 8.76 (dd, 1H, 
Ar), 8.54 (dd, 1H, Ar), 7.45 (dd, 1H, Ar), 7.27-7.20 (m, 5H, Ar), 5.72 (s, 2H, CH2), 3.85 (m, 
1H, CH), 1.89-1.30 (m, 10H, cyclohexyl). Anal. C22H23N3O2  C, H, N.  
 
N-Cyclohexyl-1-(p-fluorbenzyl)-1,8-naphtyridin-2(1H)-on-3-carboxamide 83. 
Yield: 8.44%; mp 202-205°C; 1H NMR: δ 9.56 (d,1H, NH) 8.95 (s, 1H, Ar), 8.77 (dd, 1H, 
Ar), 8.53 (dd, 1H, Ar), 7.47 (dd, 1H, Ar), 7.36-7.06 (m, 4H, Ar), 5.68 (s, 2H, NCH2), 3.80 (br, 
1H, CH), 1.88-1.22 (m, 10H, 5CH2). Anal. C22H20N3O2F C, H, N.   
 
N-Cyclohexyl-1-butyl-1,8-naphthyridin-2(1H)-on-3-carboxamide 84. 
 Yield: 55%; mp 152-154 °C; 1H NMR: δ 9.69 (d, 1H, NH), 8.88 (s, 1H, Ar), 8.79 (dd, 1H, 
Ar), 8.49 (dd, 1H, Ar), 7.45 (dd, 1H, Ar), 4.47 (t, 2H, CH2), 3.82 (m, 1H, CH), 1.89-0.88 (m, 
17H, cyclohexyl + 2CH2 + CH3). Anal. C19H25N3O2  C, H, N.  
 
N-(4-Methylcyclohexyl)-1-benzyl-1,8-naphtyridin-2(1H)-on-3-carboxamide 85. 
 Yield: 75%; mp 171-174°C. 1H NMR: δ 9.84, 9.47 (2s, 1H, NH), 8.97 (s, 1H, Ar), 8.77 (dd, 
1H, Ar), 8.57 (dd, 1H, Ar), 7.51 (m, 2H, Ar), 7.30 (m, 4H, Ar), 5.73, 5.78 (2s, 2H, CH2), 4.10, 
3.75  (2m, 1H, CH),  1.94-0.99 (m, 9H, 4CH2 + CH),  0.94,0.89 (2d, 3H, CH3). Anal. 
C23H25N3O2  C, H, N.  
 
N-(4-Methylcyclohexyl)-1-(2-morpholin-4-yl-ethyl)-1,8-naphthyridin-2(1H)-on-3-
carboxamide 86. 
Yield: 33%; mp 142-144 °C; 1H NMR: δ 9.90, 9.52 (2s, 1H, NH), 8.90 (d, 1H, Ar), 8.79 (d, 
1H, Ar), 8.50 (dd, 1H, Ar), 7.45 (dd, 1H, Ar), 4.65 (m, 2H, CH2), 4.00, 3.75 (2m, 1H, CH), 
3.51 (m, 4H, morpholine), 2.56 (m, 6H, morpholine + CH2), 0.92, 0.88 (2d, 3H) 1.90-0.87 (m, 
9H,). Anal. C22H30N4O3  C, H, N.  
 
N-Cyclohexyl-1-(2-morpholin-4-yl-ethyl)-1,8-naphthyridin-2(1H)-on-3-carboxamide 87. 
 Yield: 56%; mp 148-152 °C; 1H NMR: δ 9.80 (d, 1H, NH), 8.88 (s, 1H, Ar), 8.78 (dd, 1H, 
Ar), 8.50 (dd, 1H, Ar), 7.45 (m, 1H, Ar), 4.64 (t, 2H, CH2), 3.90 (m, 1H, CH), 3.51 (m, 4H, 
morpholine), 2.57 (m, 6H, morpholine), 1.89-1.22 (m, 10H, 5CH2). Anal. C21H28N4O3  C, H, 
N. 
 
 N-(β-phenylethyl)-1-benzyl-1,8-naphthyridin-2(1H)-on-3-carboxamide 88. 
Yield: 98%; mp 219-222°C;  1H NMR: δ 9.64 (t, 1H, NH), 8.96 (s,1H, Ar), 8.77 (d, 1H, Ar), 
8.53 (d, 1H, Ar), 7.47 (dd, 1H, Ar), 7.39-7.09 (m, 10H, Ar), 5.72 (s, 2H, CH2), 3.59 (m, 2H, 
CH2), 2.86 (tr, 2H, CH2). Anal. C24H21N3O2  C, H, N. 
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 N-(4-fluoro-phenylethyl)-1-benzyl-1,8-naphthyridin-2(1H)-on-3-carboxamide 89. 
 Yield: 87%; mp 182-185°C;  1H NMR: δ 9.72 (brs, 1H, NH), 8.93 (s, 1H, Ar), 8.78 (dd, 1H, 
Ar), 8.43 (dd, 1H, Ar), 7.49-7.23 (m, 8H, Ar), 7.11-7.02 (m, 2H, Ar),  5.82 (s, 2H, CH2) 3.69 
(m, 2H, CH2), 2.95 (tr, 2H, CH2). Anal. C24H21N3O2  C, H, N. 
 
 N-Cycloheptyl-1-benzyl-1,8-naphthyridin-2(1H)-on-3-carboxamide 90. 
 Yield: 88%; mp 171-175°C;  1H NMR: δ 9.62 (d, 1H, NH), 8.95 (s, 1H, Ar), 8.76 (dd, 1H, 
Ar), 8.53 (dd, 1H, Ar), 7.46 (dd, 1H, Ar), 7.30-7.20 (m, 5H, Ar), 5.72 (s, 2H, CH2), 4.09 (m, 
1H, CH), 1.90-0.85 (m, 12H, cycloheptyl). Anal. C25H25N3O2  C, H, N.  
 
N-(4-Methylcyclohexyl)-1-(p-fluorbenzyl)-1,8-naphtyridin-2(1H)-on-3-carboxamide 91. 
Yield 74 %; mp 143-147°C;  1H NMR: δ 9.85, 9.43 (2d, 1H, NH), 8.95, 8.97 (2s, 1H, Ar), 
8.77 (dd, 1H, Ar), 8.52 (dd, 1H, Ar), 7.47 (dd, 1H, Ar), 7.31 (m, 2H, Ar), 7.10 (m, 2H, Ar) 
5.72, 5.69 (2s, 2H, CH2), 4.10, 3.70  (2m, 1H, CH),  1.94-0.99 (m, 9H, 4CH2 + CH), 0.92, 
0.88 (2d, 3H, CH3).  
 
Cycloheptyl-1-(p-fluorbenzyl)-1,8-naphtyridin-2(1H)-on-3-carboxamide 92. 
Yield: 97.04%; mp 160-163°C; 1H NMR: δ  9.78 (d, 1H, NH); 8.88 (s, 1H, Ar); 8.75 (dd, 1H, 
Ar); 8.12 (m, 3H, Ar); 7.48 (dd, 1H, Ar); 6.94 (m, 2H, Ar); 5.78 (s, 2H, CH2); 4.10 (m, 1H, 
CH); 1.88-1.01 (m, 12H, cycloheptyl).  
 
 N-Cycloheptyl-1-(2-morpholin-4-yl-ethyl)-1,8-naphthyridin-2(1H)-on-3-carboxamide 
93. 
Yield: 64%; mp 154-158 °C; 1H NMR: δ  9.77 (d, 1H, NH), 8.88 (s, 1H, Ar), 8.68 (dd, 1H, 
Ar), 8.08 (dd, 1H, Ar), 7.28 (dd, 1H, Ar), 4.78 (tr, 2H, CH2), 4.10 (m, 1H, CH), 3.70 (m, 4H, 
morpholine), 2.78-2.65 (m, 6H, 4Hmorpholine+CH2), 2.05-0.85 (m, 12H, cycloheptyl). Anal. 
C22H30N4O3  C, H, N.  
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Experimental part scheme 11 
 
Methyl-2-amino-3-pyridinecarboxylate 94. 
A mixture of 250 mg (1.80 mmol) of 2-aminonicotinic acid  and 1.8 ml of concentrated H2SO4 
in 3.6 ml of CH3OH was heated at 80°C for 7h. After cooling the CH3OH was removed by 
evaporation under reduced pressure and the remaining mixture was neutralized with the 
solution of  NaHCO3 (pH 7-8). The precipitate thus formed was collected by filtration. 
Yield: 88%; mp 79-82°C;  1H NMR: DMSO δ 8.20 (dd, 1H, Ar), 8.05 (dd, 1H, Ar), 7.12 (br, 
2H, NH2), 6.63 (dd, 1H, Ar), 3.80 (s, 3H, OCH3). Anal. C7H8N2O2  C, H, N. 
 
 
Ethyl-4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridin-3-carboxilate 95.  
A solution of Na (0.22 g, 9.87 mmol) in anhydrous ethanol (8.23 mL) was added to 1.58 g of 
diethylmalonate (9.87 mmol) and the mixture was stirred at room temperature. After 5 min, 
the methyl-2-amino-nicotincarboxilate (0.5 g, 3.29 mmol) was added and the mixture was 
heated under reflux for 6h. The cooled mixture was diluted with 8.23 mL of water and then 
acidified with concentrated HCl. The precipitate thus formed was collected by filtration and 
crystallized from ethanol.  
Yield  58%; mp 145-148 °C; 1H NMR: δ 11.30 (br, 1H, NH), 8.53 (m, 1H, Ar), 8.30 (m, 1H, 
Ar), 7.22 (m, 1H, Ar), 4.24 (q, 2H,  CH2), 1.23 (t, 3H, CH3) . Anal. C11H10N2O4  C, H, N. 
 
N-Cyclohexyl-4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridin-3-carboxamide 96.  
A mixture of ethyl-4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridin-3-carboxilate 95 (0.20 g, 
0.85 mmol) and cyclohexylamine (0.97 mL, 10 mmol) in a sealed tube was placed in the 
microwave CEM 2000 using one-step procedure: 20 min. at 140°C at 100 psi (1 psi= 6.89 
KPa). After cooling, the reaction mixture was treated with ethyl ether to give a solid which 
was collected by filtration and crystallized from ethyl acetate.  
Yield  90%; mp 253-255 °C; 1H NMR: δ 10.04 (br, 1H, NH), 8.79 (m, 1H, Ar), 8.46 (m, 1H, 
Ar), 7.31 (dd, 1H, Ar), 3.97 (br, 1H,  CH), 2.01-0.86 (m, 10H, cyclohexyl) . Anal. C15H17N3O3  
C, H, N. 
 
 General procedure to the synthesis of N1-Substituted-4-hydroxy-2-oxo-1,2-dihydro-1,8-
naphthyridin-3-carboxamide 97, 98.  
To a solution of N-Cyclohexyl-4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridin-3-carboxamide 
74 (0.20 g, 0.69 mmol) in 6.96 mL of dry DMF,  NaH (3.42 mmol, 50 % in mineral oil) was 
added. After 1h, 4-(2-chloroethyl)-morpholine hydrochloride  or benzyl chloride (0.69 mmol) 
was added and the mixture was stirred for 24h at 50°C. After cooling, in the case of 75 the 
solvent was evaporated in vacuo and the semisolid obtained was treated with water and 
collected by filtration. For 97, the reaction mixture was treated with water and then the 
precipitate formed was  collected by filtration.  
 
N-Cyclohexyl-1-(2-morpholin-4-yl-ethyl)-4-hydroxy-2-oxo-1,2-dihydro-1,8-
naphthyridin-3-carboxamide 97.  
yield 17%; mp 247-250 °C (crystallized from ethyl acetate). 1H NMR: δ 10.20 (d, 1H, NH), 
8.80 (d, 1H, H5), 8.40 (d, 1H, H7), 7.40 (m, 1H, H6), 4.52 (t, 2H, CH2), 3.90 (m, 1H, CH), 3.52 
(m, 4H, morpholine), 2.50 (m, 6H, morpholine+CH2),  1.88-1.22 (m, 10H, cyclohexyl). Anal. 
C21H28N4O4  C, H, N.  
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N-Cyclohexyl-1-benzyl-4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridin-3-carboxamide 
98. 
 yield 18%; mp 143-145 °C (crystallized from CHCl3). 1H NMR: δ 10.20 (d, 1H, NH), 8.76 (d, 
1H, H5), 8.48 (d, 1H, H7), 7.44 (m, 1H, H6), 7.26 (m, 5H, Ar), 5.61 (s, 2H, CH2), 3.85 (m, 1H, 
CH), 1.87-1.22 (m, 10H, cyclohexyl). Anal. C22H23N3O3  C, H, N. 
 
 
 
 
 
Experimental part scheme 12 
 
 
N-Phenyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide 99. 
 A solution of aniline (0.24 mL, 2.69 mmol) and triethylmethancarboxilate (1.83 mL, 8.61 
mmol) was placed in the microwave CEM 2000 (open vessel) using one-step procedure: 15 
min. at 210 °C at 200 psi (1 psi= 6.89 KPa). After cooling, the reaction mixture was treated 
with petroleum ether to give a pure solid which was collected by filtration. 
 Yield  27%; mp 193-195 °C; 1H NMR: δ 12.10 (s, 1H, NH), 8.00 (d, 1H, Ar), 7.67 (m, 3H, 
Ar), 7.37 (m, 5H, Ar). Anal. C16H12N2O3  C, H, N. 
 
General procedure to the synthesis of N1-Substituted-4-hydroxy-2-oxo-1,2-dihydro 
quinoline-3-carboxamide 100, 101. 
To a hot solution (50 °C) of N-Phenyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide 
99 (0.12 g, 0.42 mmol) in 4.18 mL of dry DMF,  NaH (2.11 mmol, 50 % in mineral oil) was 
added. After 1h, 4-(2-chloroethyl)-morpholine hydrochloride  or benzyl chloride (0.42 mmol) 
was added and the mixture was stirred for 24 h at room temperature 100 or at 50 °C 101. After 
cooling, in the case of 100 the reaction mixture was treated with water and then the precipitate 
formed was  collected by filtration. For 101 the solvent was evaporated in vacuo and the 
semisolid obtained was treated with water and collected by filtration. 
 
N-Phenyl-4-hydroxy-1-(2-morpholin-4-yl-ethyl)-2-oxo-1,2-dihydroquinoline-3-
carboxamide 100.  
Yield 51%; mp 173-175 °C (crystallized from ethanol); 1H NMR: δ 8.13 (d, 1H, Ar), 7.85 (m, 
1H, Ar), 7.67 (d, 2H, Ar), 7.41 (m, 3H, Ar), 7.20 (m, 2H, Ar), 4.43 (t, 2H, CH2), 3.56 (m, 4H, 
morpholine), 2.50 (m, 8H, morpholine+CH2). Anal. C22H23N3O4  C, H, N.  
 
1-Benzyl-4-hydroxy-N-phenyl-2-oxo-1,2-dihydroquinoline-3-carboxamide 101. 
 yield 11%; mp 195-197 °C (crystallized from ethyl acetate); 1H NMR: δ 8.19 (d, 1H, Ar), 
7.73-7.20 (m, 13H, Ar), 5.61 (s, 2H, CH2). Anal. C23H18N2O3  C, H, N. 
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Experimental part scheme 13 
 
Methyl 2-oxo-1,2-dihydro-3-pyridinecarboxylate 102. 
A mixture of 750 mg (5,40 mmol) of 1,2-dihydro-2-oxo-3-pyridinecarboxylic acid (2-
hydroxynicotinic acid) and 5,4 ml of concentrated H2SO4 in 10,8 ml of CH3OH was heated in 
microware (CEM) to 80°C for 55 minute ( power 200W, pressure 100psi, stirring on). After 
cooling the CH3OH was removed by evaporation under reduced pressure. The remaining 
mixture was neutralized with the solution of NaHCO3 (pH 7-8). The desired compound was 
extracted with methylene chloride by the mixture. The organic layer was dried over anhydrous 
MgSO4, filtered and evaporated under reduced pressure to give 102 as a white solid (748 mg), 
which was recrystallizated from toluene. 
Yield: 91%; mp 150-154°C; 1H NMR: DMSO δ 8.08 (d, 1H, H4), 7,68 (d, 1H, H6), 6,29 (t, 
1H, H5), 3,39 (s, 1H, OH). 
 
General Procedure for the Synthesis of 2-oxo-1,2-dihydro-3-pyridinecarboxamide 
derivatives 103-105.  
A mixture of  1,0 mmol of methyl 2-oxo-1,2-dihydro-3-pyridinecarboxylic acid and  10,0 
mmol  of  suitable amide, were heated in microwave to 140°C for 60 minute (power 200W, 
pressure 100psi, stirring on) for amide 103, and  were heated at 120°C in oil bath  for 15 h for 
amide 104 or heated at 150°C for 72 h for amide 105. After cooling the reactions were treated 
with ethyl ether to give 103-105 as  solids residue, which were collected by filtration and 
purified by crystallization (crystallized from ethyl acetate for compounds 103 and 104) and 
purified by flash chromatography for compound 105. (petroleumether/ethylacetate 1:1). 
 
2-oxo-1,2-dihydro-3-pyridinecarboxycyclohexylamide  103. 
Yield: 65%; mp 195-198°C; 1H NMR: DMSO δ 9,87 (d, 1H, NH), 8,35 (d, 1H, H4), 7,73 (d, 
1H, H6), 6,50 (t, 1H, H5), 3,80 (m, 1H, NCH), 1,85-1,29 (m, 10H, cyclohexyl). 
 
2-oxo-1,2-dihydro-3-pyridinecarboxycyclohepthylamide  104. 
Yield: 67,87%; mp 138-145°C; 1H NMR: DMSO δ 9,88 (d, 1H, NH), 8,32 (d, 1H, H4), 7,71 
(d, 1H, H6), 6,48 (t, 1H, H5), 3,99 (m, 1H, NCH), 2,10-1,48 (m, 12H, cycloheptyl). 
 
2-oxo-1,2-dihypyridinecarboxy-4-methylcyclohexylamide 105. 
Yield:  63,52 %; mp 248-250° C; 1H NMR: DMSO δ 10.03; 9.08 (2d, 1H, NH ); 8.33 (d, 1H, 
H3); 7.74 (d, 1H, H5 ); 6.42 (t, 1H, H4 ); 4.05; 3.65  (2s, 1H, NCH ); 2.00 – 0.92 (m, 12H, 
cyclohexyl + CH3). 
 
General Procedure for the Synthesis of N1-Substitutedpyridine Derivatives 106-111 
An amount of 1,2 mmol of NaH  (50% in mineral oil) was added to a solution of 1 mmol of 
103-105 in 10 mL of dry N,N-dimethylformamide. After 1 h, the appropriate chloride (1 
mmol) was added and the mixture was stirred for 2,5 h at r.t.. The reaction mixture, after 
cooling  was concentrated under reduced pressure and the residue was treated with H2O and 
extracted with CH2Cl2. The organic layer was dried over anhydrous MgSO4, collected by 
filtration, and evaporated  under reduced pressure. The oily obtained was purified by flash 
chromatography (exane/ethyl acetate 10:5)  for compounds 106, 108 and 110. For the 
compound 107, 109 and 111 the mixture was concentrated under reduced pressure and  the 
residue was treated with H2O to give a white solid which was collected by filtration and 
purified by crystallization from hexane. 
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1-benzyl-2-oxo-3-pyridinecarboxycyclohexylamide 106.  
Yield: 43%; mp 65-68°C; 1H NMR: CDCl3 δ 9.75 (d, 1H, NH), 8.37 (d, 1H, H4), 8.20 (d, 1H, 
H6), 7.57-7.17 (m, 5H, Ar), 6.59 (t, 1H, H5), 5.26 (s, 2H, NCH2), 3.98 (m, 1H, NCH), 1.84-
1.28 (m, 10H, cyclohexyl).  
 
1-[4-(2-cloroethyl)morpholine]- 2-oxo-3-pyridinecarboxycyclohexylamide 107. 
Yield: 51%; mp 94-98°C; 1H NMR CDCl3 δ 9.74 (d, 1H, NH), 8.55 (dd, 1H, H6), 7.53 (dd, 
1H, H4), 6.42 (t, 1H, H5), 4.13 (t, 2H, NCH2), 4.01-3.99 (m, 1H, NCH), 3.70 (t, 4H, 
morpholine), 2.73 (t, 2H, NCH2), 2.52 (t, 4H, morpholine), 2.02-1.27 (m, 10H, cyclohexyl). 
 
1-[4-fluoro-benzyl]-2-oxo-3-pyridinecarboxycyclohexylamide 108. 
Yield: 19%; mp 120-125°C; 1H NMR: CDCl3 δ 9.71 (d, 1H, NH), 8.56 (d, 1H, H4), 7.50 (d, 
1H, H6), 7.31 (t, 4H, Ar), 6.43 (t, 1H, H5), 5.21 (s, 2H, NCH2), 3.99 (m, 1H, NCH), 2.03-1.23 
(m, 10H, cyclohexyl). 
 
1-[4-fluoro-benzyl]-2-oxo-3-pyridinecarboxycycloheptylamide 109. 
Yield: 73,68%;m.p. 118-120° C; 1H NMR: CDCl3 δ 9.77 (s, 1H, NH), 8.57 (d, 1H, H4), 7.50 
(d, 1H, H6), 7.29 (t, 4H, Ar), 6.43 (t, 1H, H5), 5.22 (s, 2H, NCH2), 4.18 (m, 1H, NCH), 2.01-
0.90  (m, 12H, cycloheptyl). 
 
1-benzyl-2-oxo-3-pyridinecarboxycycloheptylamide 110. 
Yield: 38%; 1H NMR: CDCl3 δ 9.80 (d, 1H, NH), 8.54 (d, 1H, H4), 7.46 (d, 1H, H6), 7.33 (t, 
5H, Ar), 6.41 (t, 1H, H5), 5.24 (s, 2H, CH2), 4.18-4.14 (m, 1H, NCH), 2.03-1.27 (m, 12H, 
cycloheptyl).  
 
1-[4-(2-cloroethyl)morpholine]- 2-oxo-3-pyridinecarboxycycloheptylamide 111. 
Yield: 43.33%;m.p. 40-45° C; 1H NMR: CDCl3 δ 9.90 (d, 1H, NH), 8.53 (d, 1H, H4), 7.52 (d, 
1H, H6), 6.40 (t, 1H, H5), 4.12 (t, 2H, NCH2), 4.01-3.99 (m,1H, NCH), 3.68 (t, 4H, 
morpholine), 2.73 (t, 2H, NCH2), 2.53 (t, 4H, morpholine), 2.02-1.27 (m, 12H, cycloheptyl). 
 
1-[4-fluoro-benzyl]-2-oxo-3-pyridinecarboxy-4-methylcyclohexylamide112. 
An amount of  0,250 g  (5,48 mmol ) of NaH was added to a solution of 0,640 g ( 2,74 mmol ) 
of compound 105 in 37,29 ml of DMF. After 2 h 0,328 ml ( 0,396  g; 2,74 mmol ) of 4-fluro-
benzyl chloride was added and the mixture was stirred for 24 h at room temperature. The 
mixture was concentrated under reduced pressure and the residue was treated with H2O to 
give  112 as yellow oil.  The compound was purified by chromatography using Petroleum 
ether / AcOEt  (1 : 4).  
Yield: 20.33%; mp: 33 – 35° C;  1H NMR: CDCl3 9.98; 9.59 (2d, 1H, NH), 8.57 (d, 1H, H4), 
7.52 (m, 1H, Ar), 7.34 (m, 2H, Ar), 7.12 (m, 2H, Ar), 6.41 (m, 1H, Ar), 5.22 (d, 2H, NCH2), 
4.23; 3.92 (2d, 1H, NCH), 2.03 – 1.22 (m, 12H, cyclohexyl + CH3). 
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